Next Article in Journal
Characterisation of a Staphylococcus aureus Isolate Carrying Phage-Borne Enterotoxin E from a European Badger (Meles meles)
Next Article in Special Issue
Trypanosoma cruzi STIB980: A TcI Strain for Drug Discovery and Reverse Genetics
Previous Article in Journal
Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis
Previous Article in Special Issue
Behind Base J: The Roles of JBP1 and JBP2 on Trypanosomatids
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host

Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India
School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi 110067, India
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
Author to whom correspondence should be addressed.
Pathogens 2023, 12(5), 706;
Submission received: 20 December 2022 / Revised: 8 May 2023 / Accepted: 9 May 2023 / Published: 12 May 2023


Leishmaniasis, a category 1 neglected protozoan disease caused by a kinetoplastid pathogen called Leishmania, is transmitted through dipteran insect vectors (phlebotomine, sand flies) in three main clinical forms: fatal visceral leishmaniasis, self-healing cutaneous leishmaniasis, and mucocutaneous leishmaniasis. Generic pentavalent antimonials have long been the drug of choice against leishmaniasis; however, their success is plagued with limitations such as drug resistance and severe side effects, which makes them redundant as frontline therapy for endemic visceral leishmaniasis. Alternative therapeutic regimens based on amphotericin B, miltefosine, and paromomycin have also been approved. Due to the unavailability of human vaccines, first-line chemotherapies such as pentavalent antimonials, pentamidine, and amphotericin B are the only options to treat infected individuals. The higher toxicity, adverse effects, and perceived cost of these pharmaceutics, coupled with the emergence of parasite resistance and disease relapse, makes it urgent to identify new, rationalized drug targets for the improvement in disease management and palliative care for patients. This has become an emergent need and more relevant due to the lack of information on validated molecular resistance markers for the monitoring and surveillance of changes in drug sensitivity and resistance. The present study reviewed the recent advances in chemotherapeutic regimens by targeting novel drugs using several strategies including bioinformatics to gain new insight into leishmaniasis. Leishmania has unique enzymes and biochemical pathways that are distinct from those of its mammalian hosts. In light of the limited number of available antileishmanial drugs, the identification of novel drug targets and studying the molecular and cellular aspects of these drugs in the parasite and its host is critical to design specific inhibitors targeting and controlling the parasite. The biochemical characterization of unique Leishmania-specific enzymes can be used as tools to read through possible drug targets. In this review, we discuss relevant metabolic pathways and novel drugs that are unique, essential, and linked to the survival of the parasite based on bioinformatics and cellular and biochemical analyses.

1. Introduction

Leishmaniasis is a group of vector-borne infectious protozoan diseases endemic to nearly one hundred countries [1]. Leishmaniasis is considered by the WHO to be a neglected tropical disease and a major international health challenge. In addition to malaria, it is the deadliest parasitic disease worldwide. Nearly 0.71–1 million new cases and approximately 20,000 to 65,000 deaths are reported annually, predominantly in socioeconomically vulnerable communities with limited access to essential medicines. Over 20 different species of Leishmania are reported to be infective to humans, categorized as Old World (Mediterranean countries, Asia, and Africa) and New World (America) forms. The dipteran fly Phlebotomus and its subspecies in the Old World and Lutzomyia in the New World are proven vectors for human leishmaniasis. The disease globally affects approximately 14 million people, with over one billion people at high risk of infection [2]. A World Health Organization (WHO)-sponsored epidemiological report indicates that there are nearly 12 million active cases of leishmaniasis. The incidence of cutaneous leishmaniasis is two to three times more common than visceral leishmaniasis [3,4]. At present, this disease results in 20,000 to 65,000 deaths reported annually and is included among the 18 most neglected tropical diseases (NTDs). Approximately one hundred species of these dipteran insects belonging to the genera Phlebotomus and Lutzomyia are known as the main vectors involved in biological transmission [4]. Leishmania has a complex life cycle characterized by the presence of digenetic stages: flagellated promastigotes and flagellated amastigotes [5]. The metacyclic promastigote form in sand flies is responsible for infection in healthy individuals. The amastigote form is known for its pathogenesis, having a spherical shape with a rudimentary flagellum. Amastigotes reside, propagate, and persist within the host’s mononuclear phagocytic cells [6]. Leishmaniasis represents a wide spectrum pathology ranging from less severe and self-curable cutaneous leishmaniasis (CL) to more severe and fatal visceral leishmaniasis (VL). The clinical symptoms due to parasitic infections are classified into three types of disease: cutaneous, mucocutaneous, and visceral leishmaniasis [5,6]. Cutaneous leishmaniasis is manifested by the development of skin lesions and is the most common type prevalent in the Middle East. Visceral leishmaniasis, on the other hand, is distinguished by the occurrence of hepatosplenomegaly, fever, and weight loss, and is considered as a serious health hazard for the infected individual. Mucocutaneous leishmaniasis (MCL) is characterized by damage to oral mucous membranes in the nose, mouth, and throat, which potentiates inflammation and face disfiguration [7]. Recently, a new subgenus, Mundinia, has been reported, and a member of this group (L. martiniquensis) causes VL in Southeast Asian regions. L. martiniquensis typically causes VL in humans and can be treated with amphotericin B as a first-line chemotherapeutic option. It has been reported that VL caused by L. martiniquensis has a higher relapse rate and occurs in individuals with HIV infection [8,9].
In addition to two other kinetoplastid pathogens, viz. for Trypanosoma cruzi and Trypanosoma brucei, the management of leishmaniasis requires integrated and multidisciplinary strategies that include vector control, enhanced diagnostics, and increased awareness of new therapies with safe and efficient medicines [10]. There is still no effective vaccine available, and the control of the disease primarily rests on chemotherapy, the majority of which is costly and has a wide array of side effects [10,11]. Pentavalent antimonials (sodium stibogluconate, meglumine antimoniate or generic formulations) have been used as standard drugs in countries such as India and Nepal for over 60 years and remain the primary treatment options in many endemic regions despite widespread parasite resistance [12,13]. A single dose of the polyene antibiotic amphotericin B demonstrated a 95% efficiency against visceral leishmaniasis in India [14]. Intravenous administration of liposomal amphotericin B has become a standard treatment in many countries but remains expensive, even for single-course treatments [15,16]. Miltefosine, an alkyl-lysophospholipid analog, was initially developed as an anticancer compound and is considered as a first-line effective oral drug against Leishmania [17,18]. Miltefosine has been used successfully for the treatment of VL in India since 2002 and has been incorporated into the visceral leishmaniasis elimination program for the Indian subcontinent [19]. Despite some success, miltefosine administration registers considerable resistance, with relapse in nearly 20% of patients post-treatment [20]. Miltefosine was also found to be effective against cutaneous and mucocutaneous leishmaniasis in South America, with considerable differences in percent success in therapy programs [21,22,23]. Recently, the aminoglycoside paromomycin has been approved for the treatment of VL. The efficacy of paromomycin against VL patients has been demonstrated in phase III clinical trials in India [24,25]. However, paromomycin has also shown shortcomings in efficacy across geographical regions, as demonstrated by its less than satisfactory trial in Sudan compared to India [26,27]. It is known that the drugs used act via different cellular and molecular mechanisms, causing a variety of outcomes including the apoptosis of parasites, but are also widely associated with variable toxicity and setbacks in sought-after results. These difficulties are further complicated by the emergence of drug resistance against parasites across the globe that have persisted alongside conventional chemotherapy practiced in endemic areas. This significantly lowers the susceptibility to drugs and the emergence of difficult-to-treat resistant variants of the same species [28,29,30].
Many investigators have highlighted the need to discover new drug targets employing the knowledge of parasite biochemistry to develop revolutionary new drugs by using emerging technologies. Several natural and synthetic drugs as well as repurposed drugs have been screened and attempted against free parasites in clinical scenarios. Anti-leishmanial peptides are one such strategy that has recently gained in importance, particularly with active promotion strategies by pharmaceutical companies [31,32]. The commercialization of peptide-based drugs needs to rely heavily on their utility and clinical success with ease of synthesis, water solubility, sound biocompatibility, selectivity, versatility, tenability, and low toxicity [33]. Antimicrobial peptides (AMPs) are small molecules (<100 amino acids long) with positive charges and amphipathic specificities (hydrophobic and hydrophilic regions). AMPs act by affecting membranes by destabilization/disruption of phospholipids and induce cell death by increasing the permeability of the cell membrane and are less likely to be selective to resistant variants [34,35]. AMPs also pass through the membrane and interrupt or destabilize nucleic acid or protein synthesis and/or compromise enzyme (protease) functions or cell membrane synthesis. Thus, AMPs are an interesting candidate for effective therapeutic success against leishmaniasis [36]. The leishmanicidal effects of these peptides have been published in recent reports including the structural characteristics and inevitable challenges [37,38,39]. In the present work, we have compiled and analyzed the main advances and trends in drug development against Leishmania including contributions from our laboratory for the identification and experimental evaluation of future therapeutics.

2. Chemotherapy in Leishmaniasis: Current Drugs, Limitations, and Challenges

The focus of this section relates to the discussion on the currently existing drugs in use for the treatment of VL. These include pentavalent antimonials, pentamidine, various formulations of amphotericin B (AmB), paromomycin, and miltefosine (Table 1 and Figure 1). These medications are also in use for the treatment of CL and MCL and PKDL. Treatment of VL considerably varies between the endemic regions spanning from India to Africa. The WHO approved and recommended regimens for known endemic VL foci are summarized in Table 1. Approximately 25 drugs or combinations are in use for humans with leishmaniasis [40,41,42].
WHO-OMS (2004) declared that liposomal amphotericin B, miltefosine, and paromomycin are the most promising drugs for the treatment of leishmanial infections. The search for potential new drugs and targets has been a very active area of research in the last couple of decades, with the publication of several important reviews [43,44,45,46,47,48,49,50,51,52,53,54,55,56].
Table 1. Details of the FDA-approved drugs for leishmaniasis, summarizing the cellular and molecular targets and limitations including side effects.
Table 1. Details of the FDA-approved drugs for leishmaniasis, summarizing the cellular and molecular targets and limitations including side effects.
Pathogens 12 00706 i001i.v. or i.m.
First-line treatment.
between 35 and
95% based
on area.
High resistance in some regions of India.VL, CLCardiotoxicity
arthralgia, anorexia, fever,
urticaria and significant
toxicity to the liver, kidneys, and spleen. Hospitalization
and constant monitoring of
patients during treatment
are needed.
ParomomycinPathogens 12 00706 i002i.m.A Phase III trial of Paromomycin (15 mg kg−1 (11 mg base) for 21 days showed 95% cure rate. Effective against PKDL.No effective resistance.CL, PKDLPain at the injection site, kidney toxicity, liver toxicity, and hearing toxicity.[25,59]
Amphotericin BPathogens 12 00706 i003i.v.
Very effective in regions with resistance.
>90%No effective resistance.VLInfusion-related reactions, anemia, nephrotoxicity, myocarditis, and even death of the patient.[14,60]
PentamidinePathogens 12 00706 i004Pentamidine is a second-line leishmaniasis treatment that is mostly used for CL.With cure rates ranging from 35% with L. braziliensis in Peru to 90% with L. guyanensis in Suriname, efficacy is very variable.YesCL, VLHeart damage, joint pain, loss of appetite, fever, urticaria, and serious liver, kidneys, and spleen damage. During treatment, patients must be hospitalized and constantly watched.[55,61]
MiltefosinePathogens 12 00706 i005p.o.
Increasing treatment failures.
93–95% in India, 65–85% in Africa.No effective resistance described.CL, VLIt can cause birth defects, stomach problems, kidney damage, and liver damage and cannot be given to pregnant women.[62,63]
A wide range of compounds of multiple families have been identified as potential hits and leads, and some of which are in clinical trials. Several candidates such as inhibitors impairing thiol metabolism, sterol, glycolytic, folate and trypanothione metabolism, etc. are important to consider (Table 2). These drugs and the commonly used chemotherapy (Table 1) still lack the ability to provide efficient control against Leishmania. Several combinations have been employed in clinical practice [11,64] including less toxic drug delivery systems (DDSs) such as PLGA nanoparticles or liposomes [55], poly-aggregated forms of AmpB [65], or amphiphilic antimony [66]. Below, we describe in more detail the current treatment options including their inadequacies and the need for new chemical entities.

2.1. Antimonials

Pentavalent antimonials (SbV) have been used in first-line chemotherapy based on parenteral administration available in the form of stibogluconate since 1945. It has been a sought-after monotherapy treatment for VL and is still in use against canine leishmaniasis [86,87]. Trivalent antimony (Sb+3) or emetic tartar was used against treatment for VL [57] but was later replaced by pentavalent antimony (Sb+5) compounds by Bramachari and called urea stibamine, which showed less toxicity than Sb+3 and emerged as an effective therapy against VL (kalazar) in India [88]. Pentavalent antimony is a prodrug that is converted to trivalent form to be active against the parasite. The interaction between host and intracellular amastigotes mediates the conversion [89,90]. The mechanism of action of the drug remains not completely understood and may include biochemical effects including the inhibition of DNA topoisomerase I, interference with the peculiar glutathione of trypanosomatids—trypanothione—and glycolytic enzymes [29,88,91,92]. The drug selectively accumulates intracellularly in parasites via modulation of the aqua glyceroporin AQP1 gene transporter [93,94,95], the overproduction of thiols, and the overexpression of ABC transporters (e.g., LABCI4, MRPA) [96,97,98]. Pentavalent antimony is available in two different formulations, Glucantime® and Pentostam®, with an effectiveness of approximately 90% [99]. The main reasons for the restrictive use of antimonials include side effects/toxicity and the emergence of resistance and therapeutic failures in subcontinent countries. Patients receiving antimonials experience local pain with intramuscular injection and severe side effects including cardiotoxicity, pancreatitis, hepatotoxicity, and nephrotoxicity [58,100,101] (Figure 1).

2.2. Amphotericin

Amphotericin B (AmB) is a polyene antifungal obtained through the fermentation of Streptomyces nodosusparenteris used for treating leishmaniasis and acts via differential binding to ergosterol from Leishmania membranes [102,103]. AmB is effective against different species of Leishmania and is also recommended for pregnant women and patients who are coinfected with human immune deficiency virus (HIV). The success rate of AmB is above 90%; however, similar to pentavalent antimony, it also presents high toxicity in addition to its high cost [60]. The absence of ergosterol in mammalian cells makes its leishmanicidal activity important in clinical use without any significant incidence of drug resistance. Lipid formulations (liposomal) of amphotericin B viz. AmBisome®, Amphocil®, and Abelcet® are less toxic than nonliposomal amphotericin B [104,105,106]. A phase III clinical trial with liposomal amphotericin in Bahia, Brazil for disseminated leishmaniasis, an emerging form of CL in the Americas, demonstrated a cure rate of 75% at doses >30 mg/kg [107]. Treatment with liposomal amphotericin B has fewer adverse effects and is considered more suitable for first-line treatment in Brazil [108]. In a murine model of VL, the polymeric micelle system and AmBisome® caused significant scale-down in parasite load, inducing the generation of a pathogen-specific Th1 immune response without hepatic or renal damage. Treatment with amphotericin B deoxycholate and Glucantime® caused significant toxicity to the infected animals [109] (Figure 1). Low-price liposomal AmpB (Fungisome®) and other drug delivery systems (e.g., microspheres of albumin, niosomes, chitosan, nanodisks, etc.) could be sustainable solutions for low-income regions of the world [110,111].

2.3. Miltefosine

Miltefosine, an alkyl phosphocholine derivative, was discovered as an antineoplastic agent for the treatment of cutaneous tumors, inducing apoptosis in tumor cells [112]. Miltefosine interferes with the cell membrane architecture by hindering phospholipid metabolism and affecting the synthesis of phosphatidylcholine and phosphatidylethanolamine by reducing intracellular choline [113]. The antileishmanial activity of miltefosine has been established in vivo and is now considered reliable chemotherapy against leishmaniasis with a clinical efficacy comparable to that of AmB [19,62,114]. Miltefosine is the only orally administered drug for treatment with an efficiency index of 95% in a clinical trial in India [62,63]. Miltefosine is also recommended in Ethiopia and South America [115]. The critical drawback of miltefosine administration is its long half-life (t1/2) in the organism (>120 h) plus its teratogenicity. This becomes a hindrance for its use in the fertile life of women. The efficacy of miltefosine in murine models varies depending on the type of Leishmania species. Susceptible BALB/c mice infected with L. braziliensis and L. amazonensis showed recurrence of the disease, which indicates a lack of efficiency of the drug in different types of leishmaniasis and may require very high doses for treatment [116,117,118]. Since miltefosine is taken orally, chances for the development of resistance due to self-medication habits without prescription are greater in countries such as India. The emergence of miltefosine resistance is relatively easy in L. donovani under laboratory conditions [119], and the loss of clinical efficacy has been reported [20,120,121] and confirmed in the laboratory [122] (Figure 1).

2.4. Pentamidine

Pentamidine is given intravenously or intramorally in patients who do not respond to pentavalent antimony [61]. Pentamidine showed high toxicity such as cardiotoxicity, reduction in blood pressure, and irreversible insulin-dependent diabetes mellitus [55] when used in VL. The drug binds to kinetoplastid DNA after its entry through arginine and polyamine transporters [55]. Additionally, the drug reported resistance, which has been associated with the upregulation of drug efflux, resulted in low levels of aromatic diamines in the cytosol and mitochondria [46] (Figure 1).

2.5. Paromomycin

Paromomycin (monomycin, aminosidine) is an aminoglycoside antibiotic obtained from Streptomyces krestomuceticus that acts by interfering with protein synthesis in the 16S ribosomal RNA ribosome of the target organism and inhibits respiration [123]. Paromomycin is effective against a variety of protozoan parasites (Entamoeba, Giardia, etc.) and its leishmanicidal activity has also been reported [124]. A phase III trial of paromomycin (15 mg kg−1 (11 mg base) for 21 days showed a 95% cure rate [25] and was approved in India for VL in 2006. Later, it was reported that the drug was ineffective in curing PKDL [59]. However, the application of paromomycin is plagued by the emergence of resistance when used in monotherapy despite its low cost and the absence of serious toxicity issues. Current chemotherapy for leishmaniasis has several limitations including high price, toxicity, onset of drug resistance, routes of administration, the length of treatment, and clinical failure. The emergence of severe forms of drug resistance to amphotericin B, miltefosine, etc. have increased alarmingly, particularly in endemic areas where the incidence of the outbreak is reported. It has been observed that the drugs are capable of resulting in clinical cure; however, infected individuals are not cured parasitologically, suggesting the remnants of the disease in the population. This has been reported in cutaneous and visceral Leishmania infection and is likely to be linked to the immunocompromised state of patients, where relapse is common in endemic areas in India and elsewhere. This condition highlights the impairment of the immune system due to parasite infection, suggesting the lack of effectiveness of the current drugs in inducing a long-term memory response to eradicate the disease (Table 1 and Figure 1).

3. Drug Resistance and Significance of Combination Therapy

Drug resistance is a phenomenon when the drug following selection showed reduced or no potential in its effect with reference to the susceptibility of a pathogen for a less than satisfactory effect. Clinical isolates of the pathogen have demonstrated natural variations in drug susceptibility, even in the absence of previous exposure to drugs. Reports from the Indian subcontinent have shown that parasite resistance originated mainly in areas of anthroponotic transmission [125]. Zoonotic transmission in the endemic region does not contribute to the prevalence of resistance, and only recently, unplanned urbanization may have changed this scenario, resulting in the emergence of drug-resistant parasites in those regions [126]. The incidence of HIV as a coinfection in leishmaniasis results in poor treatment outcomes with increased relapse rates and the emergence of potential drug resistance [127]. Sodium stibogluconate, meglumine antimoniate, or generic formulations have been the standard drug formulations for many decades in VL patients. In India and Nepal, the above drugs were rendered obsolete by 1995 due to drastic failure in the therapeutic efficiencies [128]. Clinical isolates of L. donovani from endemic regions have shown 3-fold less susceptibility in vitro than isolates derived from patients who respond to chemotherapy [12].
Drug resistance in Leishmania is due to the reduction in concentration of the drug in the parasite by decreased uptake mediated by the aquaglyceroporin AQP1, (the primary route of antimony entry) [129] or by the increased efflux of drug mediated by the ABC transporter ABCC3 (also known as MRPA) [96]. Antimony-resistant parasites also have increased levels of thiols (cysteine, trypanothione and glutathione) due to the overexpression/amplification of genes involved in the synthesis of glutathione and polyamines, the components of trypanothione, the main intracellular thiol in Leishmania [130,131,132,133,134]. Antimony resistance also occurs due to the inhibition of drug reduction or inactivation of the active drug [135]. Amphotericin B affects the membrane sterol of the parasite, ergosterol. Amphotericin B resistance is reported in 20% of Indian patients, where the drug was prescribed for VL patients refractory to antimonials [136]. Gene amplification in Leishmania alters the drug-binding affinity to the plasma membrane following modification in sterol composition [137]. Parasites derived from relapsing patients do not show differences in drug susceptibility in vitro [20], indicating that the reduced clinical efficacy is related to other factors such as the selection of parasites with increased virulence/infectivity, or inadequate interaction with the drug due to heterogeneous pharmacokinetics [138,139].
Miltefosine-treated parasites showed a significant reduction in mitochondrial membrane potential and cytochrome c oxidase activity [140]. Miltefosine binds to the plasma membrane and is internalized by the endocytic pathway via flippase activity mediated by the miltefosine transporter (MT) and its noncatalytic subunit Ros3. MT–Ros3 is responsible for the ATP-dependent accumulation of phosphocholine [117]. Miltefosine is excluded via exocytosis or by floppase activity, which may be mediated by the member subfamilies ABCB and ABCG of the ABC transporter [141].
In vitro susceptibility to miltefosine is intrinsically variable among the species type and clinical isolates of the pathogen [28,142]. Varying susceptibility among the different species and isolates may be due to fluctuations in the substrate specificity and activity of the MT–Ros3 machinery, rate of cell proliferation, biochemical targets, metabolism of the drug, and composition of the plasma membrane [143]. Recent studies suggest that the wide gap between in vitro susceptibility to miltefosine and treatment outcome in patients indicates an absence of correlation with the efficacy of the drug in the clinical setting [20,117]. In vitro miltefosine resistance is developed by increasing the concentration of the drug [142,144] or by chemical mutagenesis [145], likely associated with the defect in internalization of the drug, regulated by the MT–Ros3 axis. Following selection with miltefosine, MT and Ros3 genes underwent mutations, with MT genes showing a higher frequency of mutations [142,146,147,148]. MT inactivation induced a resistance phenotype in animal models of VL and CL, suggesting the importance of MT activity for the efficacy of miltefosine in vivo [142].
In CL patients, pentamidine has been used but showed toxicity when used in VL patients. Pentamidine-resistant lines obtained in vitro demonstrated alterations in the concentrations of intracellular arginine and polyamines, reduced pentamidine accumulation in the mitochondria, and augmented drug efflux [149], likely mediated by the ABC transporter PRP1 [150]. In addition, functional cloning using Cos-Seq identified a hypothetical protein that mediates the reduction in resistance to pentamidine by promastigotes [151].
Paromomycin causes alterations in the fluidity of the membrane, lipid metabolism, and mitochondrial activity. One paromomycin resistance gene has been identified in Leishmania encoding a hypothetical protein containing leucine-rich repeats conferring resistance to pentamidine [151]. Paromomycin susceptibility showed considerable heterogeneity in clinical isolates of different species of the parasite [152]. Incidence of treatment failure in leishmaniasis is a complex problem that may be caused by inappropriate handling of the drugs, patient-to-patient variability in susceptibility to the parasites, and the everlasting emergence of new isolates. In addition, pharmacokinetics and the immune response to individual drugs also play a pivotal role. The presence of Leishmania RNA virus 1 (LRV-1) in the Viannia subgenus poses an additional problem by subverting the host immune response by altering the effect of the drugs [153,154]. In light of the steady emergence of resistance against all antileishmanial drugs, a consensus on adopting combination therapy has been considered the preferred treatment option against fatal VL and others.

Combination Therapy

Adopting a combination regimen will ideally reduce the dose of individual drug and the duration of the treatment and may bring about higher compliance and lower toxicity. The combination therapy in leishmaniasis may determine the best possible options and may assure its efficacy in clinical use for the available WHO-approved drugs used mainly by VL patients from the Indian subcontinent and Africa. Combination schemes include pentavalent antimonial plus paromomycin and AmB plus miltefosine. The first combination was tested in Africa by considering the widespread prevalence of antimonial resistance in Asia. Phase 2 and 3 trials in VL patients conducted in Bihar, India have assessed the combination of liposomal AmB (single dose) plus miltefosine administered for 7, 10, or 14 days [155]. A single-dose liposomal AmB and a 10-day course of intramuscular paromomycin or a combination of miltefosine and paromomycin for 10 days were tested in VL patients [156]. All of these blends were well-tolerated and demonstrated high cure rates of ~95% with a follow-up of 6–9 months. These combinations have advantages including reduced cost and time for therapy schedule, amount of administered drug, less toxicity, and the development of drug-resistant pathogens. VL patients coinfected with HIV have comorbidities, high fatality rates, and increased drug toxicities [157]. Protease inhibitors available against treatment for HIV patients have shown leishmanicidal activity in vitro [158]. A retrospective treatment strategy for HIV–Leishmania coinfected patients with liposomal amphotericin B plus miltefosine showed a positive outcome in the scheme [159]. This includes a lower relapse rate compared with monotherapy with liposomal AmB [160].

4. Structure- and Ligand-Based Drug Design: Antileishmanial Drug Discovery

4.1. Structure-Based Drug Design (SBDD)

Combinatorial chemistry and high-throughput screening (HTS) have enabled the large-scale screening of compound libraries that include significant chemical diversity in a relatively short period [161,162]. According to sources, new medications on the market have decreased as a result of disappointing findings in various stages of clinical trials [163]. As a result, cost-effective methods for exploring and finding novel medications based on in silico or computational methods have evolved [164]. Protein structures generated by NMR or X-ray crystallography investigations are used in this method. In addition, a computationally based homology method can be used to model proteins using a variety of servers and tools. Then, for virtual screening of the protein active site pockets, small libraries of inhibitor molecules or lead compounds were produced. For this screening method, a number of docking tools are available, which aid in the discovery of the best hit compound by analyzing the compound’s binding affinity. According to Lipinski’s rule, compounds with a low binding affinity and no drug-like properties are discarded, while those with good interaction and high binding affinity are manufactured in laboratories by chemical vendors. These compounds have now been approved for use in biological systems [165]. SBDD has become a valuable tool for drug discovery and development in the field of medicine. Computational techniques and software could be used to improve the prediction of novel medications and synergistic pharmaceutical combinations to increase the treatment efficacy, avoid drug resistance, and lower dosage to avoid drug toxicity. There is some information and discussion regarding the SBDD strategy against trypanosomatides. The resources for studying leishmaniasis are listed in Table 3 and Figure 2. SBDD was utilized to find a pyrazolopyrimidine-class medication that was effective against Leishmania CDK12 (Cyclin-Dependent Kinase 12).
Lead compounds from the series proved appropriate and successful in a mouse model of infection when dosed orally twice a day for 10 days at 25 mg/kg, displaying equivalent efficacy to the front-line treatment miltefosine and decreasing parasite levels by 99% [177]. In one of the investigations, LASSBio-1386, an N-acylhydrazone derivative, was discovered to reduce the proliferation of L. amazonensis promastigotes while generating low cytotoxicity in macrophages. After in vitro treatment with LASSBio-1386, both the percentage of Leishmania-infected macrophages and the number of intracellular parasites were reduced. Furthermore, in vivo treatment of BALB/c mice infected with L. amazonensis resulted in a reduction in lesion size, parasite load, and histological architecture when compared to the controls. Molecular dynamics and docking studies were used to evaluate possible molecular interactions, and studies were performed on phosphodiesterase B1 of Leishmania (PDB code: 2R8Q) and LASSBio-1386. According to the computational research, LASSBio-1386 appears to work against Leishmania by altering leishmanial PDE (phosphodiesterase) activity [178]. Furthermore, new computational analyses are constantly being undertaken to find and propose new chemotherapy drugs [179,180,181,182].
This suggests that a computational method can assist in speeding up the development of novel anti-trypanosomatid drugs. This highly impactful approach potentiates the enhanced performance of the pharmaceutical industry in synthesizing better drugs across multifarious therapeutic horizons and has become a boon for increasingly complex disease management. Integration of computational tools into the research pipeline is an important innovation tool for finding new therapeutics. Chemoinformatics tools are classified as structure- and ligand-based drug design (SBDD and LBDD) approaches. SBDD methods use the 3D coordinates of molecular targets to study and optimize ligand–receptor interactions [183] and show the 3D architecture of numerous drug targets using X-ray crystallography. SBDD offers high affinity interactions with the targets by molecular docking, employing structure-based virtual screening (SBVS) where potential ligands are evaluated by virtue of their binding mode and energetics [184]. Structure–activity relationships (SAR) from these experiments could optimize the receptor–ligand affinity and other properties. Several macromolecular targets in Leishmania have been investigated for drug discovery. These include topoisomerases and proteases (cysteine proteases), tubulin, folate metabolism-related proteins, kinases, phosphodiesterases, and enzymes that participate in trypanothione and purine salvage pathways [185]. Ligands for these targets provide high-quality information for drug design.
Several other SBDD-based drug design attempts have been made to discover new targets against Leishmania. This includes a wide variety of pathways and biomolecules targeting the survival and physiological functions of parasites in host–parasite interactions. The list includes pteridine reductase 1 (PTR1), which is involved in the pteridine salvage pathway and folate metabolism [186]. Following molecular docking analysis using the crystal structure of L. major PTR1, active compounds were identified to have high-affinity interactions with the dihydropyrimidine and chalcone moieties of the enzyme catalytic site and leishmanicidal effects against promastigotes.
Cysteine proteases are recognized as another key enzyme responsible for parasite survival and the invasion of host cells [187]. Cathepsin-L-like endopeptidase CPB2.8 is a promising drug target in leishmaniasis. Benzimidazole derivatives displayed leishmanicidal potential against L. infantum amastigotes with binding potential to the catalytic site of CPB2.8 [188].
A novel quinalidine derivative has been identified as a suitable inhibitor against the mitochondrial enzyme NADH dehydrogenase (NDH2), which catalyzes electron transfer from NADH to ubiquinone and is another interesting candidate. Using homology modeling and pharmacophore-based virtual screening, novel NDH2 inhibitors in L. infantum have been screened for anti-leishmanial potential for in vivo studies in VL [189,190]. Quinalidine derivatives exhibit leishmanicidal activity in the nanomolar range against axenic cultures of both axenic amastigotes and promastigotes of L. infantum. SBVS of 53 leishmanial proteins including molecular dynamics simulations was performed for conformational structure following the screening of databases using the IBM World Community Grid [182]. An assembly of four proteins with high affinity interactions with the compounds in the database with the most favorable binding energy occurred in the L. major dihydroorotate dehydrogenase (LmDHODH) enzyme. LmDHODH mediates the oxidation of dihydroorotate in the pyrimidine synthesis pathway [191]. Ten top-scoring LmDHODH inhibitors were screened, selected, and assessed for in vitro leishmanicidal activity. Four of them were active against L. panamensis intracellular amastigotes, having leishmanicidal effects similar to that of the reference drug AmB. Furthermore, this drug did not show significant toxicity against human macrophages, indicating its potential for further development and future experimental studies including animal model studies.
Topoisomerase 1 of L. donovani (LdTop1) is another molecular target in the SBDD study [192]. Topoisomerase 1 causes single-strand breaks in DNA, enabling changes in topology, and is essential for cellular processes such as gene replication and transcription [193]. A series of LdTop1 inhibitors were identified by scaffold hopping and bioisosteric manipulations. Camptothecin and edotecarin are known Top1 inhibitors used as the standard starting inhibitors for constructing the molecular design. Six compounds were selected against LdTop1 by performing molecular docking studies using the crystal structures of LdTop1 and the human ortholog. Leishmanicidal activity was demonstrated against L. donovani promastigotes without any toxicity toward mammalian cells. The structure of the ternary complex 5-LdTop1-DNA, predicted by molecular docking analysis, revealed key structural aspects of the novel analogs with leishmanicidal activity without affecting the host cell cytotoxicity. Tryparedoxin peroxidase of Leishmania has been determined to be a suitable molecular target in SBDD, and the enzyme decreases hydroperoxides produced by infected macrophages. Thus, the enzyme is critically important for parasite survival [194]. Molecular docking analysis using the X-ray structure of the enzyme of Leishmania major (LmTXNPx) selected and designed a series of N,N disubstituted 3-aminomethyl quinolones with leishmanicidal properties that can be considered as suitable drug candidates against leishmaniasis.

4.2. Ligand-Based Drug Design

In cases where the X-ray 3D structure of the receptor is unavailable, a ligand-based design model is adopted to predict drug candidates. This methodology depends on information on the structure, molecular properties, and activity of the small molecules [195]. LBDD offers the construction of chemometric models that correlate molecular characteristics (molecular descriptors) with pharmacokinetic and pharmacodynamic parameters (target properties). Quantitative structure–activity and structure–property relationships (QSAR and QSPR, respectively) are derived to identify molecular characteristics that have a close relationship with the target property [196]. The LBDD protocol in combination with SBDD methods has been reported in drug discovery for leishmaniasis. LBDD uses QSAR and QSPR models for predicting activity and ADMET parameters and searches for novel compounds via ligand-based virtual screening (LBVS).

5. Design of Novel Drug Targets: Experience from our Laboratories

We studied four important cellular and biochemical pathways relevant to biochemical signaling events in Leishmania. These are associated with metabolic pathways that can be attractive targets for structure-based and ligand-based drug discovery approaches toward the development of novel antileishmanial therapeutics. We used the SBDD approach to identify putative inhibitors. In vitro and in vivo validations were performed to provide an effective platform for the evaluation of their efficiency for future antileishmanial drugs with minimal side effects. The major difficulties in SBDD application are the lack of tertiary or quaternary structures of many leishmanial proteins, which may play critical roles in numerous metabolic pathways related to housekeeping and parasite survival (Table 4 and Figure 3).

5.1. Pyruvate Phosphate Dikinase Inhibitor against Leishmania donovani

The identification of new and potentially effective inhibitors against the essential enzymes of parasites could offer new options for the treatment of VL [197].
Pyruvate phosphate dikinase (PPDK) is critical for the entry of alanine into intracellular amastigotes. The mammalian glucogenic precursor L-lactate is used by amastigotes during the synthesis of its storage carbohydrate mannogen in adverse conditions facilitated by PPDK [199]. PPDK catalyzes the reversible conversion of PPi, AMP, and phosphoenolpyruvate (PEP) into Pi, ATP, and pyruvate, respectively [200]. In mammals, the glycolytic pathway contains pyruvate kinase (PK) instead of PPDK for glucose synthesis. Thus, the absence of PPDK in humans and its indispensable role in Leishmania makes this enzyme an attractive target for antileishmanial drug design [201]. Drugs against L. donovani PPDK (LdPPDK) could be economically affordable, have less chance to develop resistance, and deliver better antileishmanial effects. We identified a putative inhibitor with ID Z220582104 and compared it with miltefosine for antileishmanial activity against free promastigotes and intracellular amastigotes (Table 4). Z220582104 was found to be safe, tolerant, and nontoxic to mammalian cells, even at very high concentrations but significantly leishmanicidal against both forms of the pathogen. However, PPDK is less effective than miltefosine [179] (Figure 3). PPDK is also considered as a potential target for developing herbicides and a target enzyme for designing new drugs [202].

5.2. UDP-Galactopyranose Mutase of Leishmania Is a Drug Target

β-Galactofuranose (β-Galf) constitutes the cell surface matrix component of Leishmania and plays an important role in the pathogenesis of the parasite [203]. UDP-galactopyranose mutase (UGM) converts UDP-galactopyranose (UDP-Galp) to UDP-galactofuranose (UDP-Galf), which acts as a precursor for β-Galf synthesis. UGM is absent in humans; thus, the enzyme is a potential target for antileishmanial drugs [204]. The 3D protein structure of L. major UGM (LmUGM) has been homology modeled by adopting Trypanosoma cruzi UGM (TcUGM) as a template. Three compounds (6064500, 44570814, and 6158954) from the PubChem database among the top hits were selected that occupied the UDP binding site of LmUGM, indicating a possible inhibitory role. In vitro antileishmanial activity was evaluated with the top ranked inhibitor 6064500 against promastigotes of L. donovani. Furthermore, at similar concentrations, the drug exhibited significantly higher levels of tolerance to mammalian cells than the standard drug miltefosine. Enamine (PubChem id: 6064500) showed concentration-dependent leishmanicidal activity against free promastigotes of L. donovani with an IC50 value equivalent to 50 μg/mL [197] (Figure 3).

5.3. Targeting Ascorbate Peroxidase of Leishmania

Oxidative stress is a host defense mechanism in macrophages that protects infected cells from pathogens by upregulating antioxidant moieties. Macrophages produce oxidative molecules (e.g., H2O2) that kill the parasites (Leishmania donovani), which in turn detoxifies the effects of H2O2 via a unique redox enzyme called ascorbate peroxidase (APX). Leishmania is deficient in catalase and glutathione (GSH) peroxidase, and thus H2O2 removal or detoxification is performed by the tryparedoxin pathway [205]. Overexpression of APX in Leishmania major (Lm-APX) protects against oxidative stress [206,207,208]. APX is important for parasite survival, and its absence in mammalian (human) hosts makes it an ideal target that could be used for therapeutic purposes. Blocking L. donovani APX (Ld-APX) in the ligand binding site by a novel inhibitor may alter the parasite’s oxidative stress potential for escape mechanisms. The crystal structure of Ld-APX is unavailable in the Research Collaboratory for Structural Bioinformatics (RCSB); thus, Ld-APX was modeled and screened using the ligand library prepared for the ascription of novel drug candidates.
Docking and MD simulation studies identified the inhibitor ZINC96021026, which is identical to the drug ML-240 that inhibits p97 ATPase activity with an approximate IC50 value of 100 nM [209]. ML-240 also inhibits p97-dependent degradation of proteasome substrates with an approximate IC50 of 900 nM [210]. AAA-ATPase p97 plays an important role in the protein homeostasis of eukaryotic cells by accentuating the degradation of ubiquitinated proteins by the proteasome and the maturation of autophagosomes [211,212]. ML-240 induces caspase 3 and 7 activation in SW403 and HCT15 cells and blocks tumor cell proliferation. ML-240 antagonizes p97 ATPase activity and was studied via high-throughput screening (HTS) of the NIH Molecular Libraries Small Molecule Repository (MLSMR) database. Our in silico observations indicated that ML-240 inhibits the ascorbate peroxidase enzyme of Leishmania. MD simulation studies showed that ML-240 is an inhibitor of APX and greatly reduced the health and growth of the promastigotes. Similar to miltefosine, ML-240 induced a concentration-dependent reduction in the viability of promastigotes. In addition, ML-240 was also potent in restricting the long-term survival and growth of the parasites. ML-240 significantly prevents the replication of amastigotes in RAW 264.7 cells and human monocyte-derived macrophages, in addition to downregulating the intensity of parasitism, defined as the phagocytic index. ML-240 treatment significantly alters the promastigote ultrastructure and downregulates the ATP levels. L. donovani-infected BALB/c mice treated with ML-240 significantly curtailed the splenic and liver parasite burden in a concentration-dependent manner. The efficiency of ML-240 treatment was on par with that of the reference drug miltefosine, which is widely used as a frontline drug candidate against kala azar (leishmaniasis). Based on these computational data and in vivo animal model studies, we proposed a new inhibitor, ZINC96021026 (ML-240), for evaluation as an antileishmanial agent (Figure 3).

5.4. Screening of Novel Inhibitors against Calcium ion Channels of Leishmania

In Leishmania, Ca2+ ions regulate several vital functions including attachment and entry inside macrophages. Human calcium channel inhibitors have a significant effect on the growth and survival of Leishmania in vitro. This suggests that the L. donovani Ca2+ ion channel (Ld-CC) is a potential drug target. Ld-CC regulates the Ca2+ ion concentration, which controls several functions including flagellar motion, mitochondrial oxidative metabolism, and entry inside host macrophages. Homology modeling of Ld-CC and docking studies of the ligand library of three datasets of 542 compounds of National Cancer Institute (NCI) diversity were performed for screening studies. ZINC17287336 and ZINC29590262 were selected as the best energy conformers, showing the highest binding affinity for the target (Ld-CC). The ligands interact with the residues in the active site of the Ld-CC pocket, indicating that the docked conformations are acceptable. Moreover, these two ligands have relatively higher binding affinity than nifedipine and verapamil, which are reported as inhibitors of calcium channels in humans with mild anti-leishmanial activity. ZINC29590262 showed better binding and affinity toward Ld-CC than the human voltage-dependent alpha-1C subunit of the L-type calcium channel. This ligand showed >40% binding affinity with Ld-CC compared with human-VDCC, suggesting leishmanicidal potential [198] (Figure 3). The role of a secondary messenger such as the Ca2+ ion regulates a wide range of cellular processes in all eukaryotic organisms [213]. The mitochondrion of the parasite (Leishmania spp.) constitutes 12% of the total volume, forming an electrochemical gradient to provide a driving force for Ca2+ entry [214]. Homeostatic disturbance in intracellular Ca2+ ions may lead to lethal morphological defects, leading to apoptosis and cell death [214]. Calcium channel blockers (CCBs) are a class of compounds that are used for hypertension and other heart ailments in humans. Targeting calcium channels could be an effective strategy for exploring new drug development strategies against Leishmania. The docking study indicates that the designed inhibitors interact with the active site residues inside the pocket of the channel, which could hinder the entry of Ca2+ ions into the parasite and thereby jeopardize intracellular Ca2+ ion homeostasis and deter parasite survival in the host. Many compounds have attracted the attention of researchers and have undergone clinical trials with the aid of structure-based drug design (SBDD) [215].

5.5. Molecular and Cellular Aspects of Novel Drug Design

Widespread drug resistance against Leishmania severely impacts health care in areas where the disease is endemic. The need and urgency of new therapeutics against Leishmania need to involve the efficiency of leishmanicidal properties against newly developed clinical isolates and optimization of the compound for monitoring clinical trials. Chemotherapy is considered as the main treatment option against leishmaniasis, although it is plagued with ever-increasing drug resistance. The development of new therapeutics against Leishmania is a pressing need. A number of metabolic pathways are essential for parasite survival and are considered prospective drug targets. Enzyme targets for biochemical characterization and their usage for drug targeting have not been extensively explored. Biosynthetic pathways including sterol, glycolytic, DNA topoisomerase, redox metabolism, polyamine biosynthesis, folate, proteases, mitogen activated protein kinase, etc. have been investigated to find new drug targets against trypanosomatid parasites including Leishmania [216]. In addition to the above-mentioned pathways, several other pathways are also critical for parasite survival. Phosphoenol pyruvate carboxykinase, pyruvate phosphate dikinase, UDP-galactopyranose mutase, etc. are essential for parasite survival. Many such enzymes are parasite specific, indicating that they are not present in the mammalian (human) host and thus offering added advantages in drug design. Resistance mechanisms against the currently used drugs include alteration in drug reduction/activation, reduced uptake, and heightened efflux/sequestration of the active molecules. In addition, the amplification of genes and the enhanced activity of the repair mechanisms following drug-induced damage also play roles in the induction of resistance. Thus, new drugs with specific microbicidal properties could free and protect the body’s physiology and immune system from cycles of failure that always pose serious challenges in therapeutic success. The absence of any viable vaccine candidate or alternative therapy against protozoan parasitic disease makes it a more urgent need for the current situation.
UDP-galactopyranose mutase (UGM) is another target and has been explored as a possible platform for antileishmanial drug targets. β-Galf is absent in humans and present in many human pathogens such as Mycobacterium tuberculosis, Leishmania spp, Trypanosoma spp, and Aspergillus fumigatus (Af) as a major cell surface component [217,218]. UGM is accountable for the virulence of these pathogens [219]. β-Galf biosynthesis requires UGM, and the enzyme is absent in the human host and is an attractive drug target against Leishmania spp. In Aspergillus fumigatus, UGM deletion leads to the loss of virulence and inhibits growth, resulting in defects in cell wall morphology [220,221]. UGM deletion increased the sensitivity of A. fumigatus toward antifungal drugs [220,221]. Targeted deletion of UGM from L. major resulted in the loss of establishment of infection in BALB/c mice [222]. Specific inhibitors against mycobacterial UGM such as synthetic aminothiazoles have been reported to inhibit microbial growth [217]. UGM inhibition of Brugiamalayi also significantly disrupts in vitro as well as in vivo antifilarial activity [223]. UDP binding to UGM induces conformational changes in the enzyme. This change causes movement of the loop, which resides opposite the substrate binding site, leading to closure of the active site and preventing diffusion of the substrate. This structural property may help in the inhibitor design against UGM [218].
In kinetoplastids including Trypanosoma, Leishmania, etc., catalase and glutathione (GSH) peroxidase are not present, and the absence of hydroperoxidase in these pathogens is based on the tryparedoxin pathway for regulating oxidative stress [224,225]. APX is a key constituent in the glutathione ascorbate cycle. Glutathione maintains a reducing atmosphere inside the cells and imparts a reduced state upon many cellular components [226]. A single copy of the APX gene of L. major plays a pivotal role in H2O2 detoxification, which is generated due to endogenous processes following external interferences that include the oxidative burst of parasite-infected macrophages or the drug metabolism of the parasite [227]. Ascorbate biosynthesis in kinetoplastids occurs in the glycosomal compartment. Treatment of catalase and peroxidase (heme-containing enzymes) with aminotriazole or sodium azide hinders the removal of H2O2 from amastigotes [225]. Overexpression of APX in L. major promastigotes enhanced the tolerance to oxidative stress-induced apoptosis. APX overexpression in the mitochondria of L. major (Lm-APX) protects the pathogen from oxidative stresses such as mitochondrial dysfunction, senescence in the cell, and alteration in cellular redox equilibrium [228]. APX gene knockdown in parasites subjected to continuous exposure to oxidative stress generates higher intracellular H2O2 content [228]. Ablation of the APX gene in L. major caused secondary effects in lipophosphoglycan (LPG) and metacyclogenesis with reference to gene expression, instigated by an alteration in the redox equilibrium of the parasites. The APX inhibitor ML-240 is a valosin-containing protein (VCP), and p97, a member of the AAA-ATPase protein inhibitor family, could be a potential candidate for leishmanicidal activity. The AAA-ATPase protein family is also involved in cellular functions including endoplasmic reticulum-associated degradation (ERAD), Golgi membrane reassembly, cell division, DNA repair, and autophagy [229,230]. Thus, targeting APX of L. donovani selectively alters the ultrastructure of the parasites and arrests ATP levels, unlike miltefosine, which also causes significant damage to the host cells.
The advantage of PPDK-specific inhibitors against Leishmania is their lack of toxicity toward human cells at very high concentrations, although they are less effective than miltefosine. PPDK was previously investigated as a logical candidate for the design and development of potential herbicides and new drugs [202,231]. An in silico study on PPDK was aimed at finding a brand-new inhibitor that is toxic to parasites but tolerant toward mammalian cells. PPDK fits well in the exploration of new therapeutics since it has different catalytic mechanisms for the glycolytic pathway.
As a result, SBDD is now a useful instrument for the creation of new drugs in the field of medicine. To boost treatment effectiveness, avoid drug resistance, and administer less medication to prevent drug toxicity, computational approaches and software could be utilized to improve the prediction of innovative pharmaceuticals and synergistic pharmacological combinations. This article discusses the SBDD Leishmania parasite defense technique. Studies on molecular dynamics and docking point to a cellular and molecular interaction between the medication and a key parasite protein. This shows that a computational approach may help hasten the creation of new anti-trypanosomatid medications. Figure 4 shows the molecular interaction between the newly identified inhibitors with important enzymes and the calcium ion channel of Leishmania. We also documented the few data that have explored drugs based on SBDD against leishmaniasis (Table 5). The proteins were downloaded from RCSB PDB and presented in a cartoon model, while inhibitors were collected from the PubChem database ( (accessed on 2 Decemeber 2022)) and shown in a 2D model using the ChemSketch tool ( (accessed on 1 December 2022)). To find potential Leishmania braziliensis N-misristoyltransferase (LbNMT) inhibitors, a hierarchical virtual screening method based on the pharmacophore model, molecular docking, and molecular dynamics was used. PyMol is a structure visualization tool. We generated 3D images of proteins after downloading their structure from the RCSB-PDB database.
According to the docking, ZINC35426134 binding is thought to stabilize the enzyme. As a result, the chosen molecule may interact with the suggested target, which supports the SBDD strategy [232]. To find prospective lead compounds, in silico virtual screening of a natural product data collection containing 800 different chemical entities was conducted against the crystal structure of the Leishmania infantum trypanothione reductase (PDB ID: 2JK6). The different potential orientations that inhibitors can achieve in the active site of trypanothione reductase have been deduced from the foot printing of protein–inhibitor interactions [234]. This opportunity to find natural compounds with potential anti-leishmanial action has been made possible by this computational approach. Computational methods were also used to target certain Leishmania pathways and associated enzymes. One of the vital processes for Leishmania survival and pathogenicity is the glycolytic pathway. Intriguing interactions between various FDA-approved and antimalarial drugs and various glycolytic enzymes such as pyruvate kinase, triosephosphate isomerase, glucose-6-phosphate isomerase, glycerol-3-phosphate dehydrogenase, and glyceraldehyde-3-phosphate dehydrogenase have been discovered through molecular docking analysis. Another pathway study recommended important enzymes such as trypanothione reductase (TR), a key player in redox homeostasis, and tryparedoxin peroxidase. The active site of these enzymes exhibits an elective binding profile for ligands, according to the molecular docking data [75,233,235,236,237] (Figure 4). The interest in bioinformatics with respect to the cellular and molecular interactions has increased. The bioinformatics-based structure-based drug design (SBDD) approach has gained attention and has benefitted the search for novel drugs against leishmaniasis.

6. Future Perspectives

Understanding drug sensitivity and resistance is critical to safeguarding the efficacy of existing treatment options and to introduce new drugs in the future. Drug resistance is a critically important issue in leishmaniasis. Chemotherapy in leishmaniasis is plagued with drug resistance, which is evident from the less than desired clinical success rates, emergence of resistance, widespread toxicity, and/or cost of current drugs, suggesting an urgent need for new effective alternatives. Additionally, new effective preclinical studies in experimental animal models representing the various forms of the disease manifestations are needed. It is extremely important to study the appropriate animal models to test novel drug candidates. Preclinical evaluation should be agreed upon and compared with the works of other investigators. The adoption of combination therapy is important for extensive clinical tests of combination schemes to introduce quantitative and qualitative changes in therapy. The goal for new effective drug development needs result-oriented collaborative research in leishmaniasis, specifically in VL, due to its alarming record of fatality. The development of new, modern, cost-effective species-specific diagnostic methods needs to be explored for wide accessibility for cutaneous and visceral forms of the disease.
Proposed actions to select preclinical candidates for the treatment of VL.
1. Stronger need to find a broader range of active molecules, either new or repurposed, against Leishmania. Repurposed drugs need to be ‘true-and-tried’ with possible better outcomes in clinical management. New small molecules are desired as anti-leishmania drug candidates with reference to their effectiveness and low toxicity as well as their low market price.
2. Identification of multitarget drugs with a strong assurance of success. New drug discovery poses some challenges due to the complexity of having to validate action on the various targets. The application of computational chemistry is important for the initial screening and for application in multitarget quantitative structure analysis relationship analysis to predict the activity of a compound with a single model.
3. Validation of mean throughput systems (MHSs) and high throughput systems (HTSs) by means of a revision of the targets and parasite stages including the relevant parasitic stage (i.e., intracellular amastigotes) and validated molecular or pathway target. Avoidance of irrelevant targets by combining automatic and phenotypic screening is necessary.
4. Application of machine learning (ML) and artificial intelligence (AI) as novel approaches to overcome challenges, viz., the cost of developing new drugs, systemic toxicity, and evolving drug resistance with reference to the current regime of antileishmanial chemotherapeutics. Attention should be given to the growth of computer processing and the development of advanced algorithms. ML algorithms and AI can be instrumental in various applications of drug discovery and improve the current process and understanding of the cause and prevention of failure in clinical trials and regulatory approval.
5. ML and AI could screen millions of compounds to predict the optimal binding that potentially inhibits the function of parasites Leishmania or Trypanosoma, presenting proper PK/PD properties to enter clinical trials. DNDi and other PDPs sought to proceed on the scale required for drug discovery.
6. ML can be employed to address the drug resistance issue that has emerged in NTD pathologies. Protein transporters (P-gp, ABC transporter, etc.) play an important role in less than optimum uptake or enhanced efflux of the drug from the pathogen and initiate drug resistance. Computer-aided algorithms may identify the parasite-specific motifs of the responsible protein transporters in Leishmania, facilitate the allosteric modulation of drug transporters, and subsequently reduce parasite resistance.
7. Appropriate and high-content transparent evaluation of the safety and toxicity in suitable models is necessary. Evaluation of the selectivity index ex vivo (against amastigotes) and toxicity in vivo (maximum tolerated dose in a standard animal model) needs to be performed. Ethical requirements and scientific evidence should be implemented for in vivo preclinical trials performed in surrogate or advanced models that need supervision from specialists (e.g., veterinarians) with expertise in the pathophysiology of animal models.
8. Stringent evaluation of the effective concentration (EC) is needed. EC90 instead of EC50 is appropriate to reduce the number of potential hits to be tested for leishmanicidal potential in vitro and ex vivo. A combination of stringent EC90 and unbiased, transparent experimental animal studies should be adopted to reach further conclusions.
9. PK/PD characterization of new inhibitors/drugs including administration routes and the inclusion of standard animal models (e.g., mice, hamsters) and nonrodents (e.g., dogs) must be preceded by preliminary pharmacological characterization (e.g., snapshot method) to determine the major pharmacological parameters (AUC, availability, half-life, excretion rate, biodistribution of the molecule, etc.). The evaluation of new molecules for in vivo antileishmanial efficacy without mandatory scientific or ethical justification may be risky and potentially nonbeneficial. Collaboration between medicinal chemists and pharmacists, immunologists, and physiologists may improve the selection of a suitable molecule for optimal presentation.
10. Socioeconomical and anthropological issues cannot be ignored in drug discovery aspects of NTDs. Human-driven environmental occurrences including deforestation, climate change, and migration contribute greatly to the dissemination of diseases such as leishmaniasis including alterations in the sylvatic and domestic cycles of parasites. This also increases resistance events and the possibility of encountering exotic strains with unknown pathophysiology. The use of standard drugs such as miltefosine in combination with newly characterized parasite-specific exclusive drugs may be a pathfinder in this kind of scenario.

7. Conclusions

New drug discovery in leishmaniasis is rooted in trial-and-error strategies based purely on phenotypic screenings and occasional testing in animal models of the disease. Despite significant advancements in therapeutics, understanding of the more intricate molecular aspects of the disease including parasite biology and cellular and molecular mechanisms of host–parasite interactions still baffles the entire spectrum of health care professionals. This paradigm reflects many unknown issues regarding trypanosomatids, specifically their drug resistance and antigenic variation potential, which is likely to be related to the cellular and molecular aspects of the disease. With the advent of the genome project in early 2000, followed by the development of a wide array of computational software and databases, the exploration of new drugs against parasitic diseases including trypanosomatids has gained momentum. The role of pharmaceutical companies, not-for-profit organizations, and academic or research institutions have together brought scientific and technological developments in the areas of genomics, proteomics, and structural biology targeting NTDs including leishmaniasis. The contribution of data banks and virtual platforms viz. Sanger Institute’s GeneDB, TDR Targets Database (WHO), etc. have been made available and organize the data of the Leishmania species, emphasizing particular gene sequences and functions connecting diverse protein and small molecule libraries. The TDR Targets Database algorithm can generate privileged combinations of novel molecular targets and compounds for experimental evaluation. LmSmdB (Leishmania major and Schistosoma mansoni database) is a comprehensive database that uses computation to account for biological networks and regulatory pathways. It streamlines and simplifies the procedure for integrating the chemicals, genes, and protein structure in order to model a disease network and assist in the selection of a molecular target. Another database, LeishMicrosatDB (Leishmania Microsatellite Database), helps in the genome-wise mining and distribution of microsatellites throughout the parasite genome. The purpose of this is to give parasitologists a platform to comprehend the characterization, mapping, phylogeny, and evolutionary analysis of genomes. The database can assist scientists choose markers at specific intervals across the chromosomes, which can be useful for immunoinformatics investigations and diagnostics. These details produce a crucial understanding of parasite diversity and molecular machinery, which is a critical factor for developing broad-spectrum antileishmanial drugs. DeepMind created an artificial intelligence (AI)-based system called AlphaFold. Based on the arrangement of the amino acids in a protein, it predicts the three-dimensional structure of the protein. This tool is also gaining interest in target structure prediction and making contributions to drug design [238,239].
This information generates a key understanding of interspecies variability and molecular machinery in parasites, which is a critical factor for developing broad-spectrum antileishmanial drugs. The Drugs for Neglected Diseases initiative (DNDi) is another Lead Optimization Latin America (LOLA) consortium focused on preclinical assessment including the pharmacokinetic efficacy and safety of the designed drugs. Chemoinformatics, in addition to experimental evaluation including in vitro and in vivo animal model studies, could provide the structure–property and structure–activity relationships that could guide the design of optimized products.

Author Contributions

R.S., M.K. and P.S. searched the literature, analyzed the data, and wrote the first draft; P.P.M. conceived, designed, and edited the article. All authors have read and agreed to the published version of the manuscript.


This work was supported by the IOE grant no. R/Dev/D/IOE/Incentive/2021-22/32275 to Partha Pratim Manna by Banaras Hindu University (BHU).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.


RS thanks the Indian Council of Medical Council Research (ICMR), India (2021-12946/CMB-BMS) for a senior research fellowship.

Conflicts of Interest

The authors declare no conflict of interest.


APXAscorbate peroxidase
CLCutaneous leishmaniasis
DHFRDihydrofolate reductase
DHFR-TSBifunctional dihydrofolate reductase-thymidylate synthase
FDAFood and Drug Administration
GAPDHglyceraldehyde 3-phosphate dehydrogenase
H2O2Hydrogen peroxide
HIVhuman immunodeficiency virus
HMGRHMG-CoA reductase
mRNAMessenger RNA
PDBProtein Data Bank
PKDLPost Kala-azar dermal leishmaniasis
PLGApoly lactic acid (PLA) and poly glycolic acid (PGA)
PRP1Proline-rich protein 1
PTR1Pteridine reductase 1
ROSReactive oxygen species
Top1DNA topoisomerase I
TRTrypanothione reductase
UDPUridine diphosphate
UGMUDP-galactopyranose mutase
VLVisceral leishmaniasis


  1. Burza, S.; Croft, S.L.; Boelaert, M. Leishmaniasis. Lancet 2018, 392, 951–970. [Google Scholar] [CrossRef] [PubMed]
  2. Torpiano, P.; Pace, D. Leishmaniasis: Diagnostic Issues in Europe. Expert. Rev. Anti. Infect. Ther. 2015, 13, 1123–1138. [Google Scholar] [CrossRef] [PubMed]
  3. Leishmaniasis. Available online: (accessed on 5 November 2022).
  4. Steverding, D. The History of Leishmaniasis. Parasites Vectors 2017, 10, 82. [Google Scholar] [CrossRef] [PubMed]
  5. Melby, P.C.; Travi, B.L.; Yaneth Osorio, E. Leishmania. In Encyclopedia of Microbiology; Elsevier: Amsterdam, The Netherlands, 2019; pp. 769–779. ISBN 978-0-12-811736-1. [Google Scholar]
  6. Gluenz, E.; Ginger, M.L.; McKean, P.G. Flagellum Assembly and Function during the Leishmania Life Cycle. Curr. Opin. Microbiol. 2010, 13, 473–479. [Google Scholar] [CrossRef] [PubMed]
  7. Piscopo, T.V.; Mallia Azzopardi, C. Leishmaniasis. Postgrad. Med. J. 2007, 83, 649–657. [Google Scholar] [CrossRef] [PubMed]
  8. Songumpai, N.; Promrangsee, C.; Noopetch, P.; Siriyasatien, P.; Preativatanyou, K. First Evidence of Co-Circulation of Emerging Leishmania Martiniquensis, Leishmania Orientalis, and Crithidia Sp. in Culicoides Biting Midges (Diptera: Ceratopogonidae), the Putative Vectors for Autochthonous Transmission in Southern Thailand. Trop. Med. Infect. Dis. 2022, 7, 379. [Google Scholar] [CrossRef]
  9. Srivarasat, S.; Brownell, N.; Siriyasatien, P.; Noppakun, N.; Asawanonda, P.; Rattanakorn, K.; Preativatanyou, K.; Kumtornrut, C. Case Report: Autochthonous Disseminated Cutaneous, Mucocutaneous, and Visceral Leishmaniasis Caused by Leishmania Martiniquensis in a Patient with HIV/AIDS from Northern Thailand and Literature Review. Am. J. Trop. Med. Hyg. 2022, 107, 1196–1202. [Google Scholar] [CrossRef] [PubMed]
  10. Alvar, J.; Arana, B.I. Appraisal of Leishmaniasis Chemotherapy, Current Status and Pipeline StrategiesChapter 1 Leishmaniasis, Impact and Therapeutic Needs; Royal Society of Chemistry: London, UK, 2017; pp. 1–23. [Google Scholar] [CrossRef]
  11. Sangshetti, J.N.; Khan, F.A.K.; Kulkarni, A.A.; Arote, R.; Patil, R.H. Antileishmanial Drug Discovery: Comprehensive Review of the Last 10 Years. RSC Adv. 2015, 5, 32376–32415. [Google Scholar] [CrossRef]
  12. Lira, R.; Sundar, S.; Makharia, A.; Kenney, R.; Gam, A.; Saraiva, E.; Sacks, D. Evidence That the High Incidence of Treatment Failures in Indian Kala-Azar Is Due to the Emergence of Antimony-Resistant Strains of Leishmania Donovani. J. Infect. Dis. 1999, 180, 564–567. [Google Scholar] [CrossRef]
  13. Sundar, S.; More, D.K.; Singh, M.K.; Singh, V.P.; Sharma, S.; Makharia, A.; Kumar, P.C.; Murray, H.W. Failure of Pentavalent Antimony in Visceral Leishmaniasis in India: Report from the Center of the Indian Epidemic. Clin. Infect. Dis. 2000, 31, 1104–1107. [Google Scholar] [CrossRef]
  14. Sundar, S.; Chakravarty, J.; Agarwal, D.; Rai, M.; Murray, H.W. Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. N. Engl. J. Med. 2010, 362, 504–512. [Google Scholar] [CrossRef] [PubMed]
  15. Bern, C.; Adler-Moore, J.; Berenguer, J.; Boelaert, M.; den Boer, M.; Davidson, R.N.; Figueras, C.; Gradoni, L.; Kafetzis, D.A.; Ritmeijer, K.; et al. Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis. Clin. Infect. Dis. 2006, 43, 917–924. [Google Scholar] [CrossRef] [PubMed]
  16. Meheus, F.; Balasegaram, M.; Olliaro, P.; Sundar, S.; Rijal, S.; Faiz, M.A.; Boelaert, M. Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent. PLoS Negl. Trop. Dis. 2010, 4, e818. [Google Scholar] [CrossRef] [PubMed]
  17. Croft, S.L.; Neal, R.A.; Pendergast, W.; Chan, J.H. The Activity of Alkyl Phosphorylcholines and Related Derivatives against Leishmania Donovani. Biochem. Pharmacol. 1987, 36, 2633–2636. [Google Scholar] [CrossRef] [PubMed]
  18. Jha, T.K.; Sundar, S.; Thakur, C.P.; Bachmann, P.; Karbwang, J.; Fischer, C.; Voss, A.; Berman, J. Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis. N. Engl. J. Med. 1999, 341, 1795–1800. [Google Scholar] [CrossRef] [PubMed]
  19. Sundar, S.; Jha, T.K.; Thakur, C.P.; Engel, J.; Sindermann, H.; Fischer, C.; Junge, K.; Bryceson, A.; Berman, J. Oral Miltefosine for Indian Visceral Leishmaniasis. N. Engl. J. Med. 2002, 347, 1739–1746. [Google Scholar] [CrossRef] [PubMed]
  20. Rijal, S.; Ostyn, B.; Uranw, S.; Rai, K.; Bhattarai, N.R.; Dorlo, T.P.C.; Beijnen, J.H.; Vanaerschot, M.; Decuypere, S.; Dhakal, S.S.; et al. Increasing Failure of Miltefosine in the Treatment of Kala-Azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance. Clin. Infect. Dis. 2013, 56, 1530–1538. [Google Scholar] [CrossRef]
  21. Soto, J.; Toledo, J.; Gutierrez, P.; Nicholls, R.S.; Padilla, J.; Engel, J.; Fischer, C.; Voss, A.; Berman, J. Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral Agent. Clin. Infect. Dis. 2001, 33, E57–E61. [Google Scholar] [CrossRef]
  22. Soto, J.; Rea, J.; Balderrama, M.; Toledo, J.; Soto, P.; Valda, L.; Berman, J.D. Efficacy of Miltefosine for Bolivian Cutaneous Leishmaniasis. Am. J. Trop. Med. Hyg. 2008, 78, 210–211. [Google Scholar] [CrossRef]
  23. Pinart, M.; Rueda, J.-R.; Romero, G.A.; Pinzón-Flórez, C.E.; Osorio-Arango, K.; Maia-Elkhoury, A.N.S.; Reveiz, L.; Elias, V.M.; Tweed, J.A. Interventions for American Cutaneous and Mucocutaneous Leishmaniasis. Cochrane Database Syst. Rev. 2020. [Google Scholar] [CrossRef]
  24. Jha, T.K.; Olliaro, P.; Thakur, C.P.N.; Kanyok, T.P.; Singhania, B.L.; Singh, I.J.; Singh, N.K.P.; Akhoury, S.; Jha, S. Randomised Controlled Trial of Aminosidine (Paromomycin) v Sodium Stibogluconate for Treating Visceral Leishmaniasis in North Bihar, India. BMJ 1998, 316, 1200–1205. [Google Scholar] [CrossRef]
  25. Sundar, S.; Jha, T.K.; Thakur, C.P.; Sinha, P.K.; Bhattacharya, S.K. Injectable Paromomycin for Visceral Leishmaniasis in India. N. Engl. J. Med. 2007, 356, 2571–2581. [Google Scholar] [CrossRef] [PubMed]
  26. Hailu, A.; Musa, A.; Wasunna, M.; Balasegaram, M.; Yifru, S.; Mengistu, G.; Hurissa, Z.; Hailu, W.; Weldegebreal, T.; Tesfaye, S.; et al. Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial. PLoS Negl. Trop. Dis. 2010, 4, e709. [Google Scholar] [CrossRef] [PubMed]
  27. Musa, A.M.; Younis, B.; Fadlalla, A.; Royce, C.; Balasegaram, M.; Wasunna, M.; Hailu, A.; Edwards, T.; Omollo, R.; Mudawi, M.; et al. Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study. PLoS Negl. Trop. Dis. 2010, 4, e855. [Google Scholar] [CrossRef]
  28. Fernández, O.L.; Diaz-Toro, Y.; Ovalle, C.; Valderrama, L.; Muvdi, S.; Rodríguez, I.; Gomez, M.A.; Saravia, N.G. Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia. PLoS Negl. Trop. Dis. 2014, 8, e2871. [Google Scholar] [CrossRef] [PubMed]
  29. Hussain, H.; Al-Harrasi, A.; Al-Rawahi, A.; Green, I.R.; Gibbons, S. Fruitful Decade for Antileishmanial Compounds from 2002 to Late 2011. Chem. Rev. 2014, 114, 10369–10428. [Google Scholar] [CrossRef]
  30. Sundar, S.; Chakravarty, J.; Meena, L.P. Leishmaniasis: Treatment, Drug Resistance and Emerging Therapies. Expert. Opin. Orphan Drugs 2019, 7, 1–10. [Google Scholar] [CrossRef]
  31. Zahedifard, F.; Rafati, S. Prospects for Antimicrobial Peptide-Based Immunotherapy Approaches in Leishmania Control. Expert. Rev. Anti. Infect. Ther. 2018, 16, 461–469. [Google Scholar] [CrossRef]
  32. Rafferty, J.; Nagaraj, H.; McCloskey, A.P.; Huwaitat, R.; Porter, S.; Albadr, A.; Laverty, G. Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients. Curr. Med. Chem. 2016, 23, 4231–4259. [Google Scholar] [CrossRef]
  33. Marqus, S.; Pirogova, E.; Piva, T.J. Evaluation of the Use of Therapeutic Peptides for Cancer Treatment. J. Biomed. Sci. 2017, 24, 21. [Google Scholar] [CrossRef]
  34. Costa, F.; Teixeira, C.; Gomes, P.; Martins, M.C.L. Clinical Application of AMPs. Adv. Exp. Med. Biol. 2019, 1117, 281–298. [Google Scholar] [CrossRef] [PubMed]
  35. Almeida, J.R.; Mendes, B.; Lancellotti, M.; Marangoni, S.; Vale, N.; Passos, Ó.; Ramos, M.J.; Fernandes, P.A.; Gomes, P.; Da Silva, S.L. A Novel Synthetic Peptide Inspired on Lys49 Phospholipase A2 from Crotalus Oreganus Abyssus Snake Venom Active against Multidrug-Resistant Clinical Isolates. Eur. J. Med. Chem. 2018, 149, 248–256. [Google Scholar] [CrossRef] [PubMed]
  36. Cobb, S.L.; Denny, P.W. Antimicrobial Peptides for Leishmaniasis. Curr. Opin. Investig. Drugs. 2010, 11, 868–875. [Google Scholar]
  37. Torrent, M.; Pulido, D.; Rivas, L.; Andreu, D. Antimicrobial Peptide Action on Parasites. Curr. Drug. Targets 2012, 13, 1138–1147. [Google Scholar] [CrossRef]
  38. Marr, A.K.; Cen, S.; Hancock, R.E.W.; McMaster, W.R. Identification of Synthetic and Natural Host Defense Peptides with Leishmanicidal Activity. Antimicrob. Agents Chemother. 2016, 60, 2484–2491. [Google Scholar] [CrossRef] [PubMed]
  39. Luque-Ortega, J.R.; Rivas, L. Characterization of the Leishmanicidal Activity of Antimicrobial Peptides. Methods Mol. Biol. 2010, 618, 393–420. [Google Scholar] [CrossRef]
  40. González, U.; Pinart, M.; Reveiz, L.; Alvar, J. Interventions for Old World Cutaneous Leishmaniasis. Cochrane Database Syst. Rev. 2008, CD005067. [Google Scholar] [CrossRef]
  41. Sundar, S.; Singh, A. Chemotherapeutics of Visceral Leishmaniasis: Present and Future Developments. Parasitology 2018, 145, 481–489. [Google Scholar] [CrossRef]
  42. Passero, L.F.D.; Brunelli, E.D.S.; Sauini, T.; Amorim Pavani, T.F.; Jesus, J.A.; Rodrigues, E. The Potential of Traditional Knowledge to Develop Effective Medicines for the Treatment of Leishmaniasis. Front. Pharmacol. 2021, 12, 690432. [Google Scholar] [CrossRef]
  43. Monzote, L. Current Treatment of Leishmaniasis: A Review. Open. Antimicrob. Agents J. 2009, 1, 9–19. [Google Scholar]
  44. Freitas-Junior, L.H.; Chatelain, E.; Kim, H.A.; Siqueira-Neto, J.L. Visceral Leishmaniasis Treatment: What Do We Have, What Do We Need and How to Deliver It? Int. J. Parasitol. Drugs Drug. Resist. 2012, 2, 11–19. [Google Scholar] [CrossRef] [PubMed]
  45. No, J.H. Visceral Leishmaniasis: Revisiting Current Treatments and Approaches for Future Discoveries. Acta Trop. 2016, 155, 113–123. [Google Scholar] [CrossRef]
  46. Singh, K.; Garg, G.; Ali, V. Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis. Curr. Drug. Metab. 2016, 17, 897–919. [Google Scholar] [CrossRef]
  47. Ponte-Sucre, A.; Gamarro, F.; Dujardin, J.-C.; Barrett, M.P.; López-Vélez, R.; García-Hernández, R.; Pountain, A.W.; Mwenechanya, R.; Papadopoulou, B. Drug Resistance and Treatment Failure in Leishmaniasis: A 21st Century Challenge. PLoS Negl. Trop. Dis. 2017, 11, e0006052. [Google Scholar] [CrossRef] [PubMed]
  48. Rivas, L.; Gil, G. Drug Discovery for Leishmaniasis; Royal Society of Chemistry: London, UK, 2018. [Google Scholar]
  49. Alves, F.; Bilbe, G.; Blesson, S.; Goyal, V.; Monnerat, S.; Mowbray, C.; Muthoni Ouattara, G.; Pécoul, B.; Rijal, S.; Rode, J.; et al. Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. Clin. Microbiol. Rev. 2018, 31, e00048-18. [Google Scholar] [CrossRef] [PubMed]
  50. Andrade-Neto, V.V.; Cunha-Junior, E.F.; Dos Santos Faioes, V.; Pereira, T.M.; Silva, R.L.; Leon, L.L.; Torres-Santos, E.C. Leishmaniasis Treatment: Update of Possibilities for Drug Repurposing. Front. Biosci. Landmark 2018, 23, 967–996. [Google Scholar] [CrossRef]
  51. Reguera, R.M.; Pérez-Pertejo, Y.; Gutiérrez-Corbo, C.; Domínguez-Asenjo, B.; Ordóñez, C.; García-Estrada, C.; Martínez-Valladares, M.; Balaña-Fouce, R. Current and Promising Novel Drug Candidates against Visceral Leishmaniasis. Pure Appl. Chem. 2019, 91, 1385–1404. [Google Scholar] [CrossRef]
  52. Uliana, S.R.B.; Trinconi, C.T.; Coelho, A.C. Chemotherapy of Leishmaniasis: Present Challenges. Parasitology 2018, 145, 464–480. [Google Scholar] [CrossRef]
  53. Sangenito, L.S.; da Silva Santos, V.; d’Avila-Levy, C.M.; Branquinha, M.H.; Souza Dos Santos, A.L.; de Oliveira, S.S.C. Leishmaniasis and Chagas Disease-Neglected Tropical Diseases: Treatment Updates. Curr. Top. Med. Chem. 2019, 19, 174–177. [Google Scholar] [CrossRef] [PubMed]
  54. van Griensven, J.; Diro, E. Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens. Infect. Dis. Clin. N. Am. 2019, 33, 79–99. [Google Scholar] [CrossRef] [PubMed]
  55. J, B.; M, B.M.; Chanda, K. An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases. Front. Chem. 2021, 9, 622286. [Google Scholar] [CrossRef] [PubMed]
  56. Sasidharan, S.; Saudagar, P. Leishmaniasis: Where Are We and Where Are We Heading? Parasitol. Res. 2021, 120, 1541–1554. [Google Scholar] [CrossRef] [PubMed]
  57. Sundar, S.; Chakravarty, J.; Rai, V.K.; Agrawal, N.; Singh, S.P.; Chauhan, V.; Murray, H.W. Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day Infusions. Clin. Infect. Dis. 2007, 45, 556–561. [Google Scholar] [CrossRef] [PubMed]
  58. de Oliveira, A.L.L.; Brustoloni, Y.M.; Fernandes, T.D.; Dorval, M.E.C.; da Cunha, R.V.; Bóia, M.N. Severe Adverse Reactions to Meglumine Antimoniate in the Treatment of Visceral Leishmaniasis: A Report of 13 Cases in the Southwestern Region of Brazil. Trop. Doct. 2009, 39, 180–182. [Google Scholar] [CrossRef]
  59. Sundar, S.; Singh, A.; Tiwari, A.; Shukla, S.; Chakravarty, J.; Rai, M. Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. ISRN Parasitol. 2014, 2014, 548010. [Google Scholar] [CrossRef]
  60. de Menezes, J.P.B.; Guedes, C.E.S.; de Oliveira Almeida Petersen, A.L.; Fraga, D.B.M.; Veras, P.S.T. Advances in Development of New Treatment for Leishmaniasis. BioMed Res. Int. 2015, 2015, e815023. [Google Scholar] [CrossRef]
  61. Andersen, E.M.; Cruz-Saldarriaga, M.; Llanos-Cuentas, A.; Luz-Cjuno, M.; Echevarria, J.; Miranda-Verastegui, C.; Colina, O.; Berman, J.D. Comparison of Meglumine Antimoniate and Pentamidine for Peruvian Cutaneous Leishmaniasis. Am. J. Trop. Med. Hyg. 2005, 72, 133–137. [Google Scholar] [CrossRef]
  62. Bhattacharya, S.K.; Sinha, P.K.; Sundar, S.; Thakur, C.P.; Jha, T.K.; Pandey, K.; Das, V.R.; Kumar, N.; Lal, C.; Verma, N.; et al. Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral Leishmaniasis. J. Infect. Dis. 2007, 196, 591–598. [Google Scholar] [CrossRef]
  63. Antinori, S.; Schifanella, L.; Corbellino, M. Leishmaniasis: New Insights from an Old and Neglected Disease. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 109–118. [Google Scholar] [CrossRef]
  64. Le Pape, P. Development of New Antileishmanial Drugs--Current Knowledge and Future Prospects. J. Enzyme Inhib. Med. Chem. 2008, 23, 708–718. [Google Scholar] [CrossRef]
  65. Torrado, J.J.; Espada, R.; Ballesteros, M.P.; Torrado-Santiago, S. Amphotericin B Formulations and Drug Targeting. J. Pharm. Sci. 2008, 97, 2405–2425. [Google Scholar] [CrossRef] [PubMed]
  66. Fernandes, F.R.; Ferreira, W.A.; Campos, M.A.; Ramos, G.S.; Kato, K.C.; Almeida, G.G.; Corrêa, J.D.; Melo, M.N.; Demicheli, C.; Frézard, F. Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis. Antimicrob. Agents Chemother. 2013, 57, 4229–4236. [Google Scholar] [CrossRef] [PubMed]
  67. Saha, S.; Acharya, C.; Pal, U.; Chowdhury, S.R.; Sarkar, K.; Maiti, N.C.; Jaisankar, P.; Majumder, H.K. A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania Donovani Parasites Both In Vitro and In Vivo by Targeting Type IB Topoisomerase. Antimicrob. Agents Chemother. 2016, 60, 6281–6293. [Google Scholar] [CrossRef] [PubMed]
  68. Leañez, J.; Nuñez, J.; García-Marchan, Y.; Sojo, F.; Arvelo, F.; Rodriguez, D.; Buscema, I.; Alvarez-Aular, A.; Bello Forero, J.S.; Kouznetsov, V.V.; et al. Anti-Leishmanial Effect of Spiro Dihydroquinoline-Oxindoles on Volume Regulation Decrease and Sterol Biosynthesis of Leishmania Braziliensis. Exp. Parasitol. 2019, 198, 31–38. [Google Scholar] [CrossRef] [PubMed]
  69. Dinesh, N.; Soumya, N.; Singh, S. Antileishmanial Effect of Mevastatin Is Due to Interference with Sterol Metabolism. Parasitol. Res. 2015, 114, 3873–3883. [Google Scholar] [CrossRef] [PubMed]
  70. Singh, S.; Babu, N.K.; Singh, S.; Babu, N.K. 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGR) Enzyme of the Sterol Biosynthetic Pathway: A Potential Target against Visceral Leishmaniasis; IntechOpen: London, UK, 2018; ISBN 978-1-78984-102-2. [Google Scholar]
  71. Tabrez, S.; Rahman, F.; Ali, R.; Akand, S.K.; Alaidarous, M.A.; Alshehri, B.M.; Banawas, S.; Dukhyil, A.A.B.; Rub, A. Targeting Sterol Alpha-14 Demethylase of Leishmania Donovani to Fight against Leishmaniasis. J. Cell Biochem. 2021, 122, 1037–1047. [Google Scholar] [CrossRef] [PubMed]
  72. Dinesh, N.; Neelagiri, S.; Kumar, V.; Singh, S. Glycyrrhizic Acid Attenuates Growth of Leishmania Donovani by Depleting Ergosterol Levels. Exp. Parasitol. 2017, 176, 21–29. [Google Scholar] [CrossRef] [PubMed]
  73. Azzouz, S.; Lawton, P. In Vitro Effects of Purine and Pyrimidine Analogues on Leishmania Donovani and Leishmania Infantum Promastigotes and Intracellular Amastigotes. Acta Parasitol. 2017, 62, 582–588. [Google Scholar] [CrossRef] [PubMed]
  74. Soysa, R.; Wilson, Z.N.; Elferich, J.; Forquer, I.; Shinde, U.; Riscoe, M.K.; Yates, P.A.; Ullman, B. Substrate Inhibition of Uracil Phosphoribosyltransferase by Uracil Can Account for the Uracil Growth Sensitivity of Leishmania Donovani Pyrimidine Auxotrophs. J. Biol. Chem. 2013, 288, 29954–29964. [Google Scholar] [CrossRef]
  75. Yousef, B.; Elwaseela, T.; Ali, T.; Mohammed, F.; Mohammed, W.; Alobaid, M.; Ibrahim Dirar, A. Anti-Malarial Drugs as Potential Inhibitors of Leishmania Glycolytic Enzymes: Development of New Anti-Leishmanial Agents. Pharmacol. Clin. Pharm. Res. 2020, 5, 77–88. [Google Scholar] [CrossRef]
  76. Verma, A.; Ghosh, S.; Salotra, P.; Singh, R. Artemisinin-Resistant Leishmania Parasite Modulates Host Cell Defense Mechanism and Exhibits Altered Expression of Unfolded Protein Response Genes. Parasitol. Res. 2019, 118, 2705–2713. [Google Scholar] [CrossRef]
  77. Hendrickx, S.; Caljon, G.; Maes, L. Need for Sustainable Approaches in Antileishmanial Drug Discovery. Parasitol. Res. 2019, 118, 2743–2752. [Google Scholar] [CrossRef] [PubMed]
  78. Wróbel, A.; Arciszewska, K.; Maliszewski, D.; Drozdowska, D. Trimethoprim and Other Nonclassical Antifolates an Excellent Template for Searching Modifications of Dihydrofolate Reductase Enzyme Inhibitors. J. Antibiot. 2020, 73, 5–27. [Google Scholar] [CrossRef]
  79. Sharma, V.K.; Bharatam, P.V. Identification of Selective Inhibitors of LdDHFR Enzyme Using Pharmacoinformatic Methods. J. Comput. Biol. 2021, 28, 43–59. [Google Scholar] [CrossRef] [PubMed]
  80. das Neves, G.M.; Kagami, L.P.; Gonçalves, I.L.; Eifler-Lima, V.L. Targeting Pteridine Reductase 1 and Dihydrofolate Reductase: The Old Is a New Trend for Leishmaniasis Drug Discovery. Future Med. Chem. 2019, 11, 2107–2130. [Google Scholar] [CrossRef]
  81. Kapil, S.; Singh, P.K.; Kashyap, A.; Silakari, O. Structure Based Designing of Benzimidazole/Benzoxazole Derivatives as Anti-Leishmanial Agents. SAR QSAR Environ. Res. 2019, 30, 919–933. [Google Scholar] [CrossRef] [PubMed]
  82. Vishwakarma, P.; Parmar, N.; Chandrakar, P.; Sharma, T.; Kathuria, M.; Agnihotri, P.K.; Siddiqi, M.I.; Mitra, K.; Kar, S. Ammonium Trichloro [1,2-Ethanediolato-O,O′]-Tellurate Cures Experimental Visceral Leishmaniasis by Redox Modulation of Leishmania Donovani Trypanothione Reductase and Inhibiting Host Integrin Linked PI3K/Akt Pathway. Cell. Mol. Life Sci. 2018, 75, 563–588. [Google Scholar] [CrossRef]
  83. Pramanik, P.K.; Chakraborti, S.; Bagchi, A.; Chakraborti, T. Bioassay-Based Corchorus Capsularis L. Leaf-Derived β-Sitosterol Exerts Antileishmanial Effects against Leishmania Donovani by Targeting Trypanothione Reductase. Sci. Rep. 2020, 10, 20440. [Google Scholar] [CrossRef]
  84. Singh, S.; Kumari, E.; Bhardwaj, R.; Kumar, R.; Dubey, V.K. Molecular Events Leading to Death of Leishmania Donovani under Spermidine Starvation after Hypericin Treatment. Chem. Biol. Drug. Des. 2017, 90, 962–971. [Google Scholar] [CrossRef]
  85. Singh, S.; Sarma, S.; Katiyar, S.P.; Das, M.; Bhardwaj, R.; Sundar, D.; Dubey, V.K. Probing the Molecular Mechanism of Hypericin-Induced Parasite Death Provides Insight into the Role of Spermidine beyond Redox Metabolism in Leishmania Donovani. Antimicrob. Agents Chemother. 2015, 59, 15–24. [Google Scholar] [CrossRef]
  86. Alvar, J.; Croft, S.; Olliaro, P. Chemotherapy in the Treatment and Control of Leishmaniasis. Adv. Parasitol. 2006, 61, 223–274. [Google Scholar] [CrossRef]
  87. Baneth, G.; Shaw, S.E. Chemotherapy of Canine Leishmaniosis. Vet. Parasitol. 2002, 106, 315–324. [Google Scholar] [CrossRef]
  88. Haldar, A.K.; Sen, P.; Roy, S. Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions. Mol. Biol. Int. 2011, 2011, 571242. [Google Scholar] [CrossRef] [PubMed]
  89. Roberts, W.L.; Rainey, P.M. Antileishmanial Activity of Sodium Stibogluconate Fractions. Antimicrob. Agents Chemother. 1993, 37, 1842–1846. [Google Scholar] [CrossRef] [PubMed]
  90. Shaked-Mishan, P.; Ulrich, N.; Ephros, M.; Zilberstein, D. Novel Intracellular SbV Reducing Activity Correlates with Antimony Susceptibility in Leishmania Donovani. J. Biol. Chem. 2001, 276, 3971–3976. [Google Scholar] [CrossRef]
  91. Wyllie, S.; Cunningham, M.L.; Fairlamb, A.H. Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania Donovani. J. Biol. Chem. 2004, 279, 39925–39932. [Google Scholar] [CrossRef] [PubMed]
  92. Frézard, F.; Monte-Neto, R.; Reis, P.G. Antimony Transport Mechanisms in Resistant Leishmania Parasites. Biophys. Rev. 2014, 6, 119–132. [Google Scholar] [CrossRef] [PubMed]
  93. Brochu, C.; Wang, J.; Roy, G.; Messier, N.; Wang, X.-Y.; Saravia, N.G.; Ouellette, M. Antimony Uptake Systems in the Protozoan Parasite Leishmania and Accumulation Differences in Antimony-Resistant Parasites. Antimicrob. Agents Chemother. 2003, 47, 3073–3079. [Google Scholar] [CrossRef]
  94. Marquis, N.; Gourbal, B.; Rosen, B.P.; Mukhopadhyay, R.; Ouellette, M. Modulation in Aquaglyceroporin AQP1 Gene Transcript Levels in Drug-Resistant Leishmania. Mol. Microbiol. 2005, 57, 1690–1699. [Google Scholar] [CrossRef]
  95. Mandal, S.; Maharjan, M.; Singh, S.; Chatterjee, M.; Madhubala, R. Assessing Aquaglyceroporin Gene Status and Expression Profile in Antimony-Susceptible and -Resistant Clinical Isolates of Leishmania Donovani from India. J. Antimicrob. Chemother. 2010, 65, 496–507. [Google Scholar] [CrossRef]
  96. Légaré, D.; Richard, D.; Mukhopadhyay, R.; Stierhof, Y.D.; Rosen, B.P.; Haimeur, A.; Papadopoulou, B.; Ouellette, M. The Leishmania ATP-Binding Cassette Protein PGPA Is an Intracellular Metal-Thiol Transporter ATPase. J. Biol. Chem. 2001, 276, 26301–26307. [Google Scholar] [CrossRef] [PubMed]
  97. Manzano, J.I.; García-Hernández, R.; Castanys, S.; Gamarro, F. A New ABC Half-Transporter in Leishmania Major Is Involved in Resistance to Antimony. Antimicrob. Agents Chemother. 2013, 57, 3719–3730. [Google Scholar] [CrossRef]
  98. Rai, S.; Bhaskar; Goel, S.K.; Dwivedi, U.N.; Sundar, S.; Goyal, N. Role of Efflux Pumps and Intracellular Thiols in Natural Antimony Resistant Isolates of Leishmania Donovani. PLoS ONE 2013, 8, e74862. [Google Scholar] [CrossRef] [PubMed]
  99. Wortmann, G.; Miller, R.S.; Oster, C.; Jackson, J.; Aronson, N. A Randomized, Double-Blind Study of the Efficacy of a 10- or 20-Day Course of Sodium Stibogluconate for Treatment of Cutaneous Leishmaniasis in United States Military Personnel. Clin. Infect. Dis. 2002, 35, 261–267. [Google Scholar] [CrossRef] [PubMed]
  100. Oliveira, L.F.; Schubach, A.O.; Martins, M.M.; Passos, S.L.; Oliveira, R.V.; Marzochi, M.C.; Andrade, C.A. Systematic Review of the Adverse Effects of Cutaneous Leishmaniasis Treatment in the New World. Acta Trop. 2011, 118, 87–96. [Google Scholar] [CrossRef] [PubMed]
  101. Wise, E.S.; Armstrong, M.S.; Watson, J.; Lockwood, D.N. Monitoring Toxicity Associated with Parenteral Sodium Stibogluconate in the Day-Case Management of Returned Travellers with New World Cutaneous Leishmaniasis [Corrected]. PLoS Negl. Trop. Dis. 2012, 6, e1688. [Google Scholar] [CrossRef]
  102. Brajtburg, J.; Powderly, W.G.; Kobayashi, G.S.; Medoff, G. Amphotericin B: Current Understanding of Mechanisms of Action. Antimicrob. Agents Chemother. 1990, 34, 183–188. [Google Scholar] [CrossRef]
  103. Ramos, H.; Valdivieso, E.; Gamargo, M.; Dagger, F.; Cohen, B.E. Amphotericin B Kills Unicellular Leishmanias by Forming Aqueous Pores Permeable to Small Cations and Anions. J. Membr. Biol. 1996, 152, 65–75. [Google Scholar] [CrossRef]
  104. Solomon, M.; Pavlotsky, F.; Leshem, E.; Ephros, M.; Trau, H.; Schwartz, E. Liposomal Amphotericin B Treatment of Cutaneous Leishmaniasis Due to Leishmania Tropica. J. Eur. Acad. Dermatol. Venereol. 2011, 25, 973–977. [Google Scholar] [CrossRef]
  105. Hamill, R.J. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs 2013, 73, 919–934. [Google Scholar] [CrossRef]
  106. Shirzadi, M.R. Lipsosomal Amphotericin B: A Review of Its Properties, Function, and Use for Treatment of Cutaneous Leishmaniasis. Res. Rep. Trop. Med. 2019, 10, 11–18. [Google Scholar] [CrossRef] [PubMed]
  107. Machado, P.R.L.; Rosa, M.E.A.; Guimarães, L.H.; Prates, F.V.O.; Queiroz, A.; Schriefer, A.; Carvalho, E.M. Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B. Clin. Infect. Dis. 2015, 61, 945–949. [Google Scholar] [CrossRef] [PubMed]
  108. Romero, G.A.S.; Costa, D.L.; Costa, C.H.N.; de Almeida, R.P.; de Melo, E.V.; de Carvalho, S.F.G.; Rabello, A.; de Carvalho, A.L.; de Queiroz Sousa, A.; Leite, R.D.; et al. Efficacy and Safety of Available Treatments for Visceral Leishmaniasis in Brazil: A Multicenter, Randomized, Open Label Trial. PLoS Negl. Trop. Dis. 2017, 11, e0005706. [Google Scholar] [CrossRef] [PubMed]
  109. Mendonça, D.V.C.; Martins, V.T.; Lage, D.P.; Dias, D.S.; Ribeiro, P.A.F.; Carvalho, A.M.R.S.; Dias, A.L.T.; Miyazaki, C.K.; Menezes-Souza, D.; Roatt, B.M.; et al. Comparing the Therapeutic Efficacy of Different Amphotericin B-Carrying Delivery Systems against Visceral Leishmaniasis. Exp. Parasitol. 2018, 186, 24–35. [Google Scholar] [CrossRef] [PubMed]
  110. Asthana, S.; Gupta, P.K.; Jaiswal, A.K.; Dube, A.; Chourasia, M.K. Targeted Chemotherapy of Visceral Leishmaniasis by Lactoferrin-Appended Amphotericin B-Loaded Nanoreservoir: In Vitro and in Vivo Studies. Nanomedicine 2015, 10, 1093–1109. [Google Scholar] [CrossRef] [PubMed]
  111. Faustino, C.; Pinheiro, L. Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics 2020, 12, 29. [Google Scholar] [CrossRef]
  112. Dorlo, T.P.C.; Balasegaram, M.; Beijnen, J.H.; de Vries, P.J. Miltefosine: A Review of Its Pharmacology and Therapeutic Efficacy in the Treatment of Leishmaniasis. J. Antimicrob. Chemother. 2012, 67, 2576–2597. [Google Scholar] [CrossRef]
  113. Rakotomanga, M.; Blanc, S.; Gaudin, K.; Chaminade, P.; Loiseau, P.M. Miltefosine Affects Lipid Metabolism in Leishmania Donovani Promastigotes. Antimicrob. Agents Chemother. 2007, 51, 1425–1430. [Google Scholar] [CrossRef]
  114. Sundar, S.; Singh, A.; Rai, M.; Prajapati, V.K.; Singh, A.K.; Ostyn, B.; Boelaert, M.; Dujardin, J.-C.; Chakravarty, J. Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India after a Decade of Use. Clin. Infect. Dis. 2012, 55, 543–550. [Google Scholar] [CrossRef]
  115. Godinho, J.L.P.; Simas-Rodrigues, C.; Silva, R.; Ürmenyi, T.P.; de Souza, W.; Rodrigues, J.C.F. Efficacy of Miltefosine Treatment in Leishmania Amazonensis-Infected BALB/c Mice. Int. J. Antimicrob. Agents 2012, 39, 326–331. [Google Scholar] [CrossRef]
  116. Coelho, A.C.; Oliveira, J.C.; Espada, C.R.; Reimão, J.Q.; Trinconi, C.T.; Uliana, S.R.B. A Luciferase-Expressing Leishmania Braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome. PLoS Negl. Trop. Dis. 2016, 10, e0004660. [Google Scholar] [CrossRef] [PubMed]
  117. Coelho, A.C.; Trinconi, C.T.; Costa, C.H.N.; Uliana, S.R.B. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania Amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up. PLoS Negl. Trop. Dis. 2016, 10, e0004720. [Google Scholar] [CrossRef] [PubMed]
  118. de Morais-Teixeira, E.; Damasceno, Q.S.; Galuppo, M.K.; Romanha, A.J.; Rabello, A. The in Vitro Leishmanicidal Activity of Hexadecylphosphocholine (Miltefosine) against Four Medically Relevant Leishmania Species of Brazil. Mem. Inst. Oswaldo Cruz. 2011, 106, 475–478. [Google Scholar] [CrossRef] [PubMed]
  119. Pérez-Victoria, F.J.; Castanys, S.; Gamarro, F. Leishmania Donovani Resistance to Miltefosine Involves a Defective Inward Translocation of the Drug. Antimicrob. Agents Chemother. 2003, 47, 2397–2403. [Google Scholar] [CrossRef] [PubMed]
  120. Deep, D.K.; Singh, R.; Bhandari, V.; Verma, A.; Sharma, V.; Wajid, S.; Sundar, S.; Ramesh, V.; Dujardin, J.C.; Salotra, P. Increased Miltefosine Tolerance in Clinical Isolates of Leishmania Donovani Is Associated with Reduced Drug Accumulation, Increased Infectivity and Resistance to Oxidative Stress. PLoS Negl. Trop. Dis. 2017, 11, e0005641. [Google Scholar] [CrossRef]
  121. Carnielli, J.B.T.; Monti-Rocha, R.; Costa, D.L.; Molina Sesana, A.; Pansini, L.N.N.; Segatto, M.; Mottram, J.C.; Costa, C.H.N.; Carvalho, S.F.G.; Dietze, R. Natural Resistance of Leishmania Infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil. Am. J. Trop. Med. Hyg. 2019, 101, 789–794. [Google Scholar] [CrossRef]
  122. Srivastava, S.; Mishra, J.; Gupta, A.K.; Singh, A.; Shankar, P.; Singh, S. Laboratory Confirmed Miltefosine Resistant Cases of Visceral Leishmaniasis from India. Parasit. Vectors 2017, 10, 49. [Google Scholar] [CrossRef]
  123. Chawla, B.; Jhingran, A.; Panigrahi, A.; Stuart, K.D.; Madhubala, R. Paromomycin Affects Translation and Vesicle-Mediated Trafficking as Revealed by Proteomics of Paromomycin -Susceptible -Resistant Leishmania Donovani. PLoS ONE 2011, 6, e26660. [Google Scholar] [CrossRef]
  124. Sinha, P.K.; Jha, T.K.; Thakur, C.P.; Nath, D.; Mukherjee, S.; Aditya, A.K.; Sundar, S. Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India. J. Trop. Med. 2011, 2011, 645203. [Google Scholar] [CrossRef]
  125. Sundar, S. Drug Resistance in Indian Visceral Leishmaniasis. Trop. Med. Int. Health 2001, 6, 849–854. [Google Scholar] [CrossRef]
  126. Harhay, M.O.; Olliaro, P.L.; Costa, D.L.; Costa, C.H.N. Urban Parasitology: Visceral Leishmaniasis in Brazil. Trends Parasitol. 2011, 27, 403–409. [Google Scholar] [CrossRef] [PubMed]
  127. Molina, R.; Gradoni, L.; Alvar, J. HIV and the Transmission of Leishmania. Ann. Trop. Med. Parasitol. 2003, 97, 29–45. [Google Scholar] [CrossRef] [PubMed]
  128. Olliaro, P.L.; Guerin, P.J.; Gerstl, S.; Haaskjold, A.A.; Rottingen, J.-A.; Sundar, S. Treatment Options for Visceral Leishmaniasis: A Systematic Review of Clinical Studies Done in India, 1980–2004. Lancet Infect. Dis. 2005, 5, 763–774. [Google Scholar] [CrossRef] [PubMed]
  129. Gourbal, B.; Sonuc, N.; Bhattacharjee, H.; Legare, D.; Sundar, S.; Ouellette, M.; Rosen, B.P.; Mukhopadhyay, R. Drug Uptake and Modulation of Drug Resistance in Leishmania by an Aquaglyceroporin. J. Biol. Chem. 2004, 279, 31010–31017. [Google Scholar] [CrossRef]
  130. Mukhopadhyay, R.; Dey, S.; Xu, N.; Gage, D.; Lightbody, J.; Ouellette, M.; Rosen, B.P. Trypanothione Overproduction and Resistance to Antimonials and Arsenicals in Leishmania. Proc. Natl. Acad. Sci. USA 1996, 93, 10383–10387. [Google Scholar] [CrossRef]
  131. Grondin, K.; Haimeur, A.; Mukhopadhyay, R.; Rosen, B.P.; Ouellette, M. Co-Amplification of the Gamma-Glutamylcysteine Synthetase Gene Gsh1 and of the ABC Transporter Gene PgpA in Arsenite-Resistant Leishmania Tarentolae. EMBO J. 1997, 16, 3057–3065. [Google Scholar] [CrossRef]
  132. Légaré, D.; Papadopoulou, B.; Roy, G.; Mukhopadhyay, R.; Haimeur, A.; Dey, S.; Grondin, K.; Brochu, C.; Rosen, B.P.; Ouellette, M. Efflux Systems and Increased Trypanothione Levels in Arsenite-ResistantLeishmania. Exp. Parasitol. 1997, 87, 275–282. [Google Scholar] [CrossRef] [PubMed]
  133. Guimond, C.; Trudel, N.; Brochu, C.; Marquis, N.; Fadili, A.E.; Peytavi, R.; Briand, G.; Richard, D.; Messier, N.; Papadopoulou, B.; et al. Modulation of Gene Expression in Leishmania Drug Resistant Mutants as Determined by Targeted DNA Microarrays. Nucleic Acids Res. 2003, 31, 5886–5896. [Google Scholar] [CrossRef] [PubMed]
  134. do Monte-Neto, R.L.; Coelho, A.C.; Raymond, F.; Légaré, D.; Corbeil, J.; Melo, M.N.; Frézard, F.; Ouellette, M. Gene Expression Profiling and Molecular Characterization of Antimony Resistance in Leishmania Amazonensis. PLoS Negl. Trop. Dis. 2011, 5, e1167. [Google Scholar] [CrossRef]
  135. Croft, S.L.; Sundar, S.; Fairlamb, A.H. Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev. 2006, 19, 111–126. [Google Scholar] [CrossRef]
  136. Purkait, B.; Singh, R.; Wasnik, K.; Das, S.; Kumar, A.; Paine, M.; Dikhit, M.; Singh, D.; Sardar, A.H.; Ghosh, A.K.; et al. Up-Regulation of Silent Information Regulator 2 (Sir2) Is Associated with Amphotericin B Resistance in Clinical Isolates of Leishmania Donovani. J. Antimicrob. Chemother. 2015, 70, 1343–1356. [Google Scholar] [CrossRef] [PubMed]
  137. Mbongo, N.; Loiseau, P.M.; Billion, M.A.; Robert-Gero, M. Mechanism of Amphotericin B Resistance in Leishmania Donovani Promastigotes. Antimicrob. Agents Chemother. 1998, 42, 352–357. [Google Scholar] [CrossRef]
  138. Rai, K.; Cuypers, B.; Bhattarai, N.R.; Uranw, S.; Berg, M.; Ostyn, B.; Dujardin, J.-C.; Rijal, S.; Vanaerschot, M. Relapse after Treatment with Miltefosine for Visceral Leishmaniasis Is Associated with Increased Infectivity of the Infecting Leishmania Donovani Strain. mBio 2013, 4, e00611-13. [Google Scholar] [CrossRef] [PubMed]
  139. Dorlo, T.P.C.; Rijal, S.; Ostyn, B.; de Vries, P.J.; Singh, R.; Bhattarai, N.; Uranw, S.; Dujardin, J.-C.; Boelaert, M.; Beijnen, J.H.; et al. Failure of Miltefosine in Visceral Leishmaniasis Is Associated With Low Drug Exposure. J. Infect. Dis. 2014, 210, 146–153. [Google Scholar] [CrossRef] [PubMed]
  140. Luque-Ortega, J.R.; Rivas, L. Miltefosine (Hexadecylphosphocholine) Inhibits Cytochrome c Oxidase in Leishmania Donovani Promastigotes. Antimicrob. Agents Chemother. 2007, 51, 1327–1332. [Google Scholar] [CrossRef]
  141. Castanys-Muñoz, E.; Pérez-Victoria, J.M.; Gamarro, F.; Castanys, S. Characterization of an ABCG-Like Transporter from the Protozoan Parasite Leishmania with a Role in Drug Resistance and Transbilayer Lipid Movement. Antimicrob. Agents Chemother. 2008, 52, 3573–3579. [Google Scholar] [CrossRef]
  142. Coelho, A.C.; Trinconi, C.T.; Costa, C.H.N.; Uliana, S.R.B. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania Amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis. PLoS Negl. Trop. Dis. 2014, 8, e2999. [Google Scholar] [CrossRef]
  143. Sánchez-Cañete, M.P.; Carvalho, L.; Pérez-Victoria, F.J.; Gamarro, F.; Castanys, S. Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania Braziliensis Refractory to the Drug. Antimicrob. Agents Chemother. 2009, 53, 1305–1313. [Google Scholar] [CrossRef]
  144. Obonaga, R.; Fernández, O.L.; Valderrama, L.; Rubiano, L.C.; del Mar Castro, M.; Barrera, M.C.; Gomez, M.A.; Gore Saravia, N. Treatment Failure and Miltefosine Susceptibility in Dermal Leishmaniasis Caused by Leishmania Subgenus Viannia Species. Antimicrob. Agents Chemother. 2014, 58, 144–152. [Google Scholar] [CrossRef]
  145. Coelho, A.C.; Trinconi, C.T.; Senra, L.; Yokoyama-Yasunaka, J.K.U.; Uliana, S.R.B. Leishmania Is Not Prone to Develop Resistance to Tamoxifen. Int. J. Parasitol. Drugs Drug. Resist. 2015, 5, 77–83. [Google Scholar] [CrossRef]
  146. Kulshrestha, A.; Sharma, V.; Singh, R.; Salotra, P. Comparative Transcript Expression Analysis of Miltefosine-Sensitive and Miltefosine-Resistant Leishmania Donovani. Parasitol. Res. 2014, 113, 1171–1184. [Google Scholar] [CrossRef]
  147. Mondelaers, A.; Sanchez-Cañete, M.P.; Hendrickx, S.; Eberhardt, E.; Garcia-Hernandez, R.; Lachaud, L.; Cotton, J.; Sanders, M.; Cuypers, B.; Imamura, H.; et al. Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania Infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes. PLoS ONE 2016, 11, e0154101. [Google Scholar] [CrossRef] [PubMed]
  148. Shaw, C.D.; Lonchamp, J.; Downing, T.; Imamura, H.; Freeman, T.M.; Cotton, J.A.; Sanders, M.; Blackburn, G.; Dujardin, J.C.; Rijal, S.; et al. In Vitro Selection of Miltefosine Resistance in Promastigotes of Leishmania Donovani from Nepal: Genomic and Metabolomic Characterization. Mol. Microbiol. 2016, 99, 1134–1148. [Google Scholar] [CrossRef] [PubMed]
  149. Basselin, M.; Denise, H.; Coombs, G.H.; Barrett, M.P. Resistance to Pentamidine in Leishmania Mexicana Involves Exclusion of the Drug from the Mitochondrion. Antimicrob. Agents Chemother. 2002, 46, 3731–3738. [Google Scholar] [CrossRef]
  150. Ac, C.; Sm, B.; Pc, C. Functional Genetic Identification of PRP1, an ABC Transporter Superfamily Member Conferring Pentamidine Resistance in Leishmania Major. Mol. Biochem. Parasitol. 2003, 130, 83–90. [Google Scholar] [CrossRef]
  151. Gazanion, É.; Fernández-Prada, C.; Papadopoulou, B.; Leprohon, P.; Ouellette, M. Cos-Seq for High-Throughput Identification of Drug Target and Resistance Mechanisms in the Protozoan Parasite Leishmania. Proc. Natl. Acad. Sci. USA 2016, 113, E3012–E3021. [Google Scholar] [CrossRef]
  152. Prajapati, V.K.; Mehrotra, S.; Gautam, S.; Rai, M.; Sundar, S. In Vitro Antileishmanial Drug Susceptibility of Clinical Isolates from Patients with Indian Visceral Leishmaniasis--Status of Newly Introduced Drugs. Am. J. Trop. Med. Hyg. 2012, 87, 655–657. [Google Scholar] [CrossRef]
  153. Adaui, V.; Lye, L.-F.; Akopyants, N.S.; Zimic, M.; Llanos-Cuentas, A.; Garcia, L.; Maes, I.; De Doncker, S.; Dobson, D.E.; Arevalo, J.; et al. Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania Braziliensis in Peru and Bolivia. J. Infect. Dis. 2016, 213, 112–121. [Google Scholar] [CrossRef]
  154. Bourreau, E.; Ginouves, M.; Prévot, G.; Hartley, M.-A.; Gangneux, J.-P.; Robert-Gangneux, F.; Dufour, J.; Sainte-Marie, D.; Bertolotti, A.; Pratlong, F.; et al. Presence of Leishmania RNA Virus 1 in Leishmania Guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse. J. Infect. Dis. 2016, 213, 105–111. [Google Scholar] [CrossRef] [PubMed]
  155. Sundar, S.; Rai, M.; Chakravarty, J.; Agarwal, D.; Agrawal, N.; Vaillant, M.; Olliaro, P.; Murray, H.W. New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine. Clin. Infect. Dis. 2008, 47, 1000–1006. [Google Scholar] [CrossRef] [PubMed]
  156. Sundar, S.; Sinha, P.K.; Rai, M.; Verma, D.K.; Nawin, K.; Alam, S.; Chakravarty, J.; Vaillant, M.; Verma, N.; Pandey, K.; et al. Comparison of Short-Course Multidrug Treatment with Standard Therapy for Visceral Leishmaniasis in India: An Open-Label, Non-Inferiority, Randomised Controlled Trial. Lancet 2011, 377, 477–486. [Google Scholar] [CrossRef] [PubMed]
  157. Alvar, J.; Aparicio, P.; Aseffa, A.; Den Boer, M.; Cañavate, C.; Dedet, J.-P.; Gradoni, L.; Ter Horst, R.; López-Vélez, R.; Moreno, J. The Relationship between Leishmaniasis and AIDS: The Second 10 Years. Clin. Microbiol. Rev. 2008, 21, 334–359, table of contents. [Google Scholar] [CrossRef] [PubMed]
  158. van Griensven, J.; Diro, E.; Lopez-Velez, R.; Boelaert, M.; Lynen, L.; Zijlstra, E.; Dujardin, J.-C.; Hailu, A. HIV-1 Protease Inhibitors for Treatment of Visceral Leishmaniasis in HIV-Co-Infected Individuals. Lancet Infect. Dis. 2013, 13, 251–259. [Google Scholar] [CrossRef] [PubMed]
  159. Mahajan, R.; Das, P.; Isaakidis, P.; Sunyoto, T.; Sagili, K.D.; Lima, M.A.; Mitra, G.; Kumar, D.; Pandey, K.; Van geertruyden, J.-P.; et al. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. Clin. Infect. Dis. 2015, 61, 1255–1262. [Google Scholar] [CrossRef] [PubMed]
  160. Burza, S.; Mahajan, R.; Sinha, P.K.; van Griensven, J.; Pandey, K.; Lima, M.A.; Sanz, M.G.; Sunyoto, T.; Kumar, S.; Mitra, G.; et al. Visceral Leishmaniasis and HIV Co-Infection in Bihar, India: Long-Term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome). PLoS Negl. Trop. Dis. 2014, 8, e3053. [Google Scholar] [CrossRef] [PubMed]
  161. Folmer, R.H.A. Integrating Biophysics with HTS-Driven Drug Discovery Projects. Drug. Discovery Today 2016, 21, 491–498. [Google Scholar] [CrossRef]
  162. Liu, R.; Li, X.; Lam, K.S. Combinatorial Chemistry in Drug Discovery. Curr. Opin. Chem. Biol. 2017, 38, 117–126. [Google Scholar] [CrossRef]
  163. Lavecchia, A.; Cerchia, C. In Silico Methods to Address Polypharmacology: Current Status, Applications and Future Perspectives. Drug. Discov. Today 2016, 21, 288–298. [Google Scholar] [CrossRef]
  164. Cheng, T.; Li, Q.; Zhou, Z.; Wang, Y.; Bryant, S.H. Structure-Based Virtual Screening for Drug Discovery: A Problem-Centric Review. AAPS J. 2012, 14, 133–141. [Google Scholar] [CrossRef]
  165. Ou-Yang, S.-S.; Lu, J.-Y.; Kong, X.-Q.; Liang, Z.-J.; Luo, C.; Jiang, H. Computational Drug Discovery. Acta Pharmacol. Sin. 2012, 33, 1131–1140. [Google Scholar] [CrossRef]
  166. Aslett, M.; Aurrecoechea, C.; Berriman, M.; Brestelli, J.; Brunk, B.P.; Carrington, M.; Depledge, D.P.; Fischer, S.; Gajria, B.; Gao, X.; et al. TriTrypDB: A Functional Genomic Resource for the Trypanosomatidae. Nucleic Acids Res. 2010, 38, D457–D462. [Google Scholar] [CrossRef] [PubMed]
  167. Saunders, E.C.; MacRae, J.I.; Naderer, T.; Ng, M.; McConville, M.J.; Likić, V.A. LeishCyc: A Guide to Building a Metabolic Pathway Database and Visualization of Metabolomic Data. Methods Mol. Biol. 2012, 881, 505–529. [Google Scholar] [CrossRef] [PubMed]
  168. Real, F.; Vidal, R.O.; Carazzolle, M.F.; Mondego, J.M.C.; Costa, G.G.L.; Herai, R.H.; Würtele, M.; de Carvalho, L.M.; Carmona e Ferreira, R.; Mortara, R.A.; et al. The Genome Sequence of Leishmania (Leishmania) Amazonensis: Functional Annotation and Extended Analysis of Gene Models. DNA Res. 2013, 20, 567–581. [Google Scholar] [CrossRef] [PubMed]
  169. Logan-Klumpler, F.J.; De Silva, N.; Boehme, U.; Rogers, M.B.; Velarde, G.; McQuillan, J.A.; Carver, T.; Aslett, M.; Olsen, C.; Subramanian, S.; et al. GeneDB--an Annotation Database for Pathogens. Nucleic Acids Res. 2012, 40, D98–D108. [Google Scholar] [CrossRef] [PubMed]
  170. Aurrecoechea, C.; Barreto, A.; Basenko, E.Y.; Brestelli, J.; Brunk, B.P.; Cade, S.; Crouch, K.; Doherty, R.; Falke, D.; Fischer, S.; et al. EuPathDB: The Eukaryotic Pathogen Genomics Database Resource. Nucleic Acids Res. 2017, 45, D581–D591. [Google Scholar] [CrossRef] [PubMed]
  171. Patel, P.; Mandlik, V.; Singh, S. LmSmdB: An Integrated Database for Metabolic and Gene Regulatory Network in Leishmania Major and Schistosoma Mansoni. Genom. Data 2016, 7, 115–118. [Google Scholar] [CrossRef]
  172. Dikhit, M.R.; Moharana, K.C.; Sahoo, B.R.; Sahoo, G.C.; Das, P. LeishMicrosatDB: Open Source Database of Repeat Sequences Detected in Six Fully Sequenced Leishmania Genomes. Database 2014, 2014, bau078. [Google Scholar] [CrossRef]
  173. Gazestani, V.H.; Yip, C.W.; Nikpour, N.; Berghuis, N.; Salavati, R. TrypsNetDB: An Integrated Framework for the Functional Characterization of Trypanosomatid Proteins. PLoS Negl. Trop. Dis. 2017, 11, e0005368. [Google Scholar] [CrossRef]
  174. Torres, F.; Arias-Carrasco, R.; Caris-Maldonado, J.C.; Barral, A.; Maracaja-Coutinho, V.; De Queiroz, A.T.L. LeishDB: A Database of Coding Gene Annotation and Non-Coding RNAs in Leishmania Braziliensis. Database 2017, 2017, bax047. [Google Scholar] [CrossRef]
  175. Waugh, B.; Ghosh, A.; Bhattacharyya, D.; Ghoshal, N.; Banerjee, R. In Silico Work Flow for Scaffold Hopping in Leishmania. BMC Res. Notes 2014, 7, 802. [Google Scholar] [CrossRef]
  176. Chavali, A.K.; Whittemore, J.D.; Eddy, J.A.; Williams, K.T.; Papin, J.A. Systems Analysis of Metabolism in the Pathogenic Trypanosomatid Leishmania Major. Mol. Syst. Biol. 2008, 4, 177. [Google Scholar] [CrossRef] [PubMed]
  177. Wyllie, S.; Thomas, M.; Patterson, S.; Crouch, S.; De Rycker, M.; Lowe, R.; Gresham, S.; Urbaniak, M.D.; Otto, T.D.; Stojanovski, L.; et al. Cyclin-Dependent Kinase 12 Is a Drug Target for Visceral Leishmaniasis. Nature 2018, 560, 192–197. [Google Scholar] [CrossRef] [PubMed]
  178. Silva, D.K.C.; Teixeira, J.S.; Moreira, D.R.M.; da Silva, T.F.; de Lacerda Barreiro, E.J.; de Freitas, H.F.; da Rocha Pita, S.S.; Teles, A.L.B.; Guimarães, E.T.; Soares, M.B.P. In Vitro, In Vivo and In Silico Effectiveness of LASSBio-1386, an N-Acyl Hydrazone Derivative Phosphodiesterase-4 Inhibitor, Against Leishmania Amazonensis. Front. Pharmacol. 2020, 11, 590544. [Google Scholar] [CrossRef] [PubMed]
  179. Kashif, M.; Hira, S.K.; Upadhyaya, A.; Gupta, U.; Singh, R.; Paladhi, A.; Khan, F.I.; Rub, A.; Manna, P.P. In Silico Studies and Evaluation of Antiparasitic Role of a Novel Pyruvate Phosphate Dikinase Inhibitor in Leishmania Donovani Infected Macrophages. Int. J. Antimicrob. Agents 2019, 53, 508–514. [Google Scholar] [CrossRef]
  180. Kashif, M.; Paladhi, A.; Singh, R.; Bhattacharyya, S.; Hira, S.K.; Manna, P.P. Leishmanicidal Activity of an In Silico-Screened Novel Inhibitor against Ascorbate Peroxidase of Leishmania Donovani. Antimicrob. Agents Chemother. 2020, 64, e01766-19. [Google Scholar] [CrossRef]
  181. Pandey, R.K.; Kumbhar, B.V.; Sundar, S.; Kunwar, A.; Prajapati, V.K. Structure-Based Virtual Screening, Molecular Docking, ADMET and Molecular Simulations to Develop Benzoxaborole Analogs as Potential Inhibitor against Leishmania Donovani Trypanothione Reductase. J. Recept. Signal. Transduct. Res. 2017, 37, 60–70. [Google Scholar] [CrossRef]
  182. Ochoa, R.; Watowich, S.J.; Flórez, A.; Mesa, C.V.; Robledo, S.M.; Muskus, C. Drug Search for Leishmaniasis: A Virtual Screening Approach by Grid Computing. J. Comput. Aided Mol. Des. 2016, 30, 541–552. [Google Scholar] [CrossRef]
  183. van Montfort, R.L.M.; Workman, P. Structure-Based Drug Design: Aiming for a Perfect Fit. Essays Biochem. 2017, 61, 431–437. [Google Scholar] [CrossRef]
  184. Ferreira, L.G.; Dos Santos, R.N.; Oliva, G.; Andricopulo, A.D. Molecular Docking and Structure-Based Drug Design Strategies. Molecules 2015, 20, 13384–13421. [Google Scholar] [CrossRef]
  185. Ansari, M.Y.; Dikhit, M.R.; Sahoo, G.C.; Ali, V.; Das, P. Recent Advancement and Treatment of Leishmaniasis Based on Pharmacoinformatics Approach: Current and Future Outlook. Gene Rep. 2017, 9, 86–97. [Google Scholar] [CrossRef]
  186. Ong, H.B.; Sienkiewicz, N.; Wyllie, S.; Fairlamb, A.H. Dissecting the Metabolic Roles of Pteridine Reductase 1 in Trypanosoma Brucei and Leishmania Major*. J. Biol. Chem. 2011, 286, 10429–10438. [Google Scholar] [CrossRef]
  187. Casgrain, P.-A.; Martel, C.; McMaster, W.R.; Mottram, J.C.; Olivier, M.; Descoteaux, A. Cysteine Peptidase B Regulates Leishmania Mexicana Virulence through the Modulation of GP63 Expression. PLoS Pathogens 2016, 12, e1005658. [Google Scholar] [CrossRef] [PubMed]
  188. De Luca, L.; Ferro, S.; Buemi, M.R.; Monforte, A.-M.; Gitto, R.; Schirmeister, T.; Maes, L.; Rescifina, A.; Micale, N. Discovery of Benzimidazole-Based Leishmania Mexicana Cysteine Protease CPB2.8ΔCTE Inhibitors as Potential Therapeutics for Leishmaniasis. Chem. Biol. Drug. Des. 2018, 92, 1585–1596. [Google Scholar] [CrossRef]
  189. Marreiros, B.C.; Sena, F.V.; Sousa, F.M.; Oliveira, A.S.F.; Soares, C.M.; Batista, A.P.; Pereira, M.M. Structural and Functional Insights into the Catalytic Mechanism of the Type II NADH:Quinone Oxidoreductase Family. Sci. Rep. 2017, 7, 42303. [Google Scholar] [CrossRef] [PubMed]
  190. Stevanović, S.; Perdih, A.; Senćanski, M.; Glišić, S.; Duarte, M.; Tomás, A.M.; Sena, F.V.; Sousa, F.M.; Pereira, M.M.; Solmajer, T. In Silico Discovery of a Substituted 6-Methoxy-Quinalidine with Leishmanicidal Activity in Leishmania Infantum. Molecules 2018, 23, 772. [Google Scholar] [CrossRef]
  191. Cordeiro, A.T.; Feliciano, P.R.; Pinheiro, M.P.; Nonato, M.C. Crystal Structure of Dihydroorotate Dehydrogenase from Leishmania Major. Biochimie 2012, 94, 1739–1748. [Google Scholar] [CrossRef]
  192. Mamidala, R.; Majumdar, P.; Jha, K.K.; Bathula, C.; Agarwal, R.; Chary, M.T.; Majumder, H.K.; Munshi, P.; Sen, S. Identification of Leishmania Donovani Topoisomerase 1 Inhibitors via Intuitive Scaffold Hopping and Bioisosteric Modification of Known Top 1 Inhibitors. Sci. Rep. 2016, 6, 26603. [Google Scholar] [CrossRef]
  193. Pommier, Y.; Sun, Y.; Huang, S.-Y.N.; Nitiss, J.L. Roles of Eukaryotic Topoisomerases in Transcription, Replication and Genomic Stability. Nat. Rev. Mol. Cell. Biol. 2016, 17, 703–721. [Google Scholar] [CrossRef]
  194. Fiorillo, A.; Colotti, G.; Boffi, A.; Baiocco, P.; Ilari, A. The Crystal Structures of the Tryparedoxin-Tryparedoxin Peroxidase Couple Unveil the Structural Determinants of Leishmania Detoxification Pathway. PLoS Negl. Trop. Dis. 2012, 6, e1781. [Google Scholar] [CrossRef]
  195. Chen, C.Y.-C. A Novel Integrated Framework and Improved Methodology of Computer-Aided Drug Design. Curr. Top. Med. Chem. 2013, 13, 965–988. [Google Scholar] [CrossRef] [PubMed]
  196. Yousefinejad, S.; Hemmateenejad, B. Chemometrics Tools in QSAR/QSPR Studies: A Historical Perspective. Chemom. Intell. Lab. Syst. 2015, 149, 177–204. [Google Scholar] [CrossRef]
  197. Kashif, M.; Tabrez, S.; Husein, A.; Arish, M.; Kalaiarasan, P.; Manna, P.P.; Subbarao, N.; Akhter, Y.; Rub, A. Identification of Novel Inhibitors against UDP-Galactopyranose Mutase to Combat Leishmaniasis. J. Cell. Biochem. 2018, 119, 2653–2665. [Google Scholar] [CrossRef] [PubMed]
  198. Kashif, M.; Manna, P.; Akhter, Y.; Alaidarous, M.; Rub, A. The Screening of Novel Inhibitors against Leishmania Donovani Calcium Ion Channel to Fight Leishmaniasis. Infect. Disord. Drug. Targets (Former. Curr. Drug. Targets Infect. Disord.) 2016, 16, 120–129. [Google Scholar] [CrossRef]
  199. Rodriguez-Contreras, D.; Hamilton, N. Gluconeogenesis in Leishmania Mexicana: Contribution of Glycerol Kinase, Phosphoenolpyruvate Carboxykinase, and Pyruvate Phosphate Dikinase. J. Biol. Chem. 2014, 289, 32989–33000. [Google Scholar] [CrossRef] [PubMed]
  200. Palayam, M.; Lakshminarayanan, K.; Radhakrishnan, M.; Krishnaswamy, G. Preliminary Analysis to Target Pyruvate Phosphate Dikinase from Wolbachia Endosymbiont of Brugia Malayi for Designing Anti-Filarial Agents. Interdiscip. Sci. Comput. Life Sci. 2012, 4, 74–82. [Google Scholar] [CrossRef]
  201. Amaro, R.E.; Baron, R.; McCammon, J.A. An Improved Relaxed Complex Scheme for Receptor Flexibility in Computer-Aided Drug Design. J. Comput. Aided Mol. Des. 2008, 22, 693–705. [Google Scholar] [CrossRef]
  202. Wu, C.; Dunaway-Mariano, D.; Mariano, P.S. Design, Synthesis, and Evaluation of Inhibitors of Pyruvate Phosphate Dikinase. Available online: (accessed on 10 November 2022).
  203. Beverley, S.M.; Owens, K.L.; Showalter, M.; Griffith, C.L.; Doering, T.L.; Jones, V.C.; McNeil, M.R. Eukaryotic UDP-Galactopyranose Mutase (GLF Gene) in Microbial and Metazoal Pathogens. Eukaryotic Cell. 2005, 4, 1147–1154. [Google Scholar] [CrossRef]
  204. Oppenheimer, M.; Valenciano, A.L.; Sobrado, P. Isolation and Characterization of Functional Leishmania Major Virulence Factor UDP-Galactopyranose Mutase. Biochem. Biophys. Res. Commun. 2011, 407, 552–556. [Google Scholar] [CrossRef]
  205. Kumar, A.; Das, S.; Purkait, B.; Sardar, A.H.; Ghosh, A.K.; Dikhit, M.R.; Abhishek, K.; Das, P. Ascorbate Peroxidase, a Key Molecule Regulating Amphotericin B Resistance in Clinical Isolates of Leishmania Donovani. Antimicrob. Agents Chemother. 2014, 58, 6172–6184. [Google Scholar] [CrossRef]
  206. Dolai, S.; Yadav, R.K.; Pal, S.; Adak, S. Overexpression of Mitochondrial Leishmania Major Ascorbate Peroxidase Enhances Tolerance to Oxidative Stress-Induced Programmed Cell Death and Protein Damage. Eukaryotic Cell. 2009, 8, 1721–1731. [Google Scholar] [CrossRef]
  207. Pal, S.; Dolai, S.; Yadav, R.K.; Adak, S. Ascorbate Peroxidase from Leishmania Major Controls the Virulence of Infective Stage of Promastigotes by Regulating Oxidative Stress. PLoS ONE 2010, 5, e11271. [Google Scholar] [CrossRef] [PubMed]
  208. Sardar, A.H.; Kumar, S.; Kumar, A.; Purkait, B.; Das, S.; Sen, A.; Kumar, M.; Sinha, K.K.; Singh, D.; Equbal, A.; et al. Proteome Changes Associated with Leishmania Donovani Promastigote Adaptation to Oxidative and Nitrosative Stresses. J. Proteom. 2013, 81, 185–199. [Google Scholar] [CrossRef] [PubMed]
  209. Chou, T.-F.; Bulfer, S.L.; Weihl, C.C.; Li, K.; Lis, L.G.; Walters, M.A.; Schoenen, F.J.; Lin, H.J.; Deshaies, R.J.; Arkin, M.R. Specific Inhibition of P97/VCP ATPase and Kinetic Analysis Demonstrate Interaction between D1 and D2 ATPase Domains. J. Mol. Biol. 2014, 426, 2886–2899. [Google Scholar] [CrossRef] [PubMed]
  210. Chou, T.-F.; Li, K.; Frankowski, K.J.; Schoenen, F.J.; Deshaies, R.J. Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of P97 ATPase. ChemMedChem 2013, 8, 297–312. [Google Scholar] [CrossRef]
  211. Chou, T.-F.; Brown, S.J.; Minond, D.; Nordin, B.E.; Li, K.; Jones, A.C.; Chase, P.; Porubsky, P.R.; Stoltz, B.M.; Schoenen, F.J.; et al. Reversible Inhibitor of P97, DBeQ, Impairs Both Ubiquitin-Dependent and Autophagic Protein Clearance Pathways. Proc. Natl. Acad. Sci. USA 2011, 108, 4834–4839. [Google Scholar] [CrossRef]
  212. Guedes Aguiar, B.; Padmanabhan, P.K.; Dumas, C.; Papadopoulou, B. Valosin-Containing Protein VCP/P97 Is Essential for the Intracellular Development of Leishmania and Its Survival under Heat Stress. Cell. Microbiol. 2018, 20, e12867. [Google Scholar] [CrossRef] [PubMed]
  213. Misra, S.; Naskar, K.; Sarkar, D.; Ghosh, D.K. Role of Ca2+ Ion on Leishmania-Macrophage Attachment. Mol. Cell. Biochem. 1991, 102, 13–18. [Google Scholar] [CrossRef]
  214. Zhivotovsky, B.; Orrenius, S. Calcium and Cell Death Mechanisms: A Perspective from the Cell Death Community. Cell. Calcium 2011, 50, 211–221. [Google Scholar] [CrossRef]
  215. Batool, M.; Ahmad, B.; Choi, S. A Structure-Based Drug Discovery Paradigm. Int. J. Mol. Sci. 2019, 20, 2783. [Google Scholar] [CrossRef]
  216. Raj, S.; Sasidharan, S.; Balaji, S.N.; Saudagar, P. An Overview of Biochemically Characterized Drug Targets in Metabolic Pathways of Leishmania Parasite. Parasitol. Res. 2020, 119, 2025–2037. [Google Scholar] [CrossRef]
  217. Dykhuizen, E.C.; May, J.F.; Tongpenyai, A.; Kiessling, L.L. Inhibitors of UDP-Galactopyranose Mutase Thwart Mycobacterial Growth. J. Am. Chem. Soc. 2008, 130, 6706–6707. [Google Scholar] [CrossRef] [PubMed]
  218. Kizjakina, K.; Tanner, J.J.; Sobrado, P. Targeting UDP-Galactopyranose Mutases from Eukaryotic Human Pathogens. Curr. Pharm. Des. 2013, 19, 2561–2573. [Google Scholar] [CrossRef] [PubMed]
  219. Pedersen, L.L.; Turco, S.J. Galactofuranose Metabolism: A Potential Target for Antimicrobial Chemotherapy. CMLS Cell. Mol. Life Sci. 2003, 60, 259–266. [Google Scholar] [CrossRef] [PubMed]
  220. Damveld, R.A.; Franken, A.; Arentshorst, M.; Punt, P.J.; Klis, F.M.; van den Hondel, C.A.M.J.J.; Ram, A.F.J. A Novel Screening Method for Cell Wall Mutants in Aspergillus Niger Identifies UDP-Galactopyranose Mutase as an Important Protein in Fungal Cell Wall Biosynthesis. Genetics 2008, 178, 873–881. [Google Scholar] [CrossRef]
  221. Schmalhorst, P.S.; Krappmann, S.; Vervecken, W.; Rohde, M.; Müller, M.; Braus, G.H.; Contreras, R.; Braun, A.; Bakker, H.; Routier, F.H. Contribution of Galactofuranose to the Virulence of the Opportunistic Pathogen Aspergillus Fumigatus. Eukaryotic Cell. 2008, 7, 1268–1277. [Google Scholar] [CrossRef] [PubMed]
  222. Kleczka, B.; Lamerz, A.-C.; van Zandbergen, G.; Wenzel, A.; Gerardy-Schahn, R.; Wiese, M.; Routier, F.H. Targeted Gene Deletion of Leishmania Major UDP-Galactopyranose Mutase Leads to Attenuated Virulence. J. Biol. Chem. 2007, 282, 10498–10505. [Google Scholar] [CrossRef] [PubMed]
  223. Misra, S.; Valicherla, G.R.; Shahab, M.; Gupta, J.; Gayen, J.R.; Misra-Bhattacharya, S. UDP-Galactopyranose Mutase, a Potential Drug Target against Human Pathogenic Nematode Brugia Malayi. Pathog. Dis. 2016, 74, ftw072. [Google Scholar] [CrossRef]
  224. de Souza Moreira, D.; Xavier, M.V.; Murta, S.M.F. Ascorbate Peroxidase Overexpression Protects Leishmania Braziliensis against Trivalent Antimony Effects. Mem. Inst. Oswaldo Cruz 2018, 113, 1–5. [Google Scholar] [CrossRef]
  225. Singh, K.; Ali, V.; Pratap Singh, K.; Gupta, P.; Suman, S.S.; Ghosh, A.K.; Bimal, S.; Pandey, K.; Das, P. Deciphering the Interplay between Cysteine Synthase and Thiol Cascade Proteins in Modulating Amphotericin B Resistance and Survival of Leishmania Donovani under Oxidative Stress. Redox Biol. 2017, 12, 350–366. [Google Scholar] [CrossRef]
  226. Das, S.; Aich, A.; Shaha, C. The Complex World of Cellular Defense in the Leishmania Parasite. Proc. Indian. Natl. Sci. Acad. 2015, 81, 629–641. [Google Scholar] [CrossRef]
  227. Adak, S.; Datta, A.K. Leishmania Major Encodes an Unusual Peroxidase That Is a Close Homologue of Plant Ascorbate Peroxidase: A Novel Role of the Transmembrane Domain. Biochem. J. 2005, 390, 465–474. [Google Scholar] [CrossRef] [PubMed]
  228. Dolai, S.; Yadav, R.K.; Pal, S.; Adak, S. Leishmania Major Ascorbate Peroxidase Overexpression Protects Cells against Reactive Oxygen Species-Mediated Cardiolipin Oxidation. Free. Radic. Biol. Med. 2008, 45, 1520–1529. [Google Scholar] [CrossRef] [PubMed]
  229. Seguin, S.J.; Morelli, F.F.; Vinet, J.; Amore, D.; De Biasi, S.; Poletti, A.; Rubinsztein, D.C.; Carra, S. Inhibition of Autophagy, Lysosome and VCP Function Impairs Stress Granule Assembly. Cell. Death Differ. 2014, 21, 1838–1851. [Google Scholar] [CrossRef] [PubMed]
  230. Mansuri, R.; Kumar, A.; Rana, S.; Panthi, B.; Ansari, M.Y.; Das, S.; Dikhit, M.R.; Sahoo, G.C.; Das, P. In Vitro Evaluation of Antileishmanial Activity of Computationally Screened Compounds against Ascorbate Peroxidase To Combat Amphotericin B Drug Resistance. Antimicrob. Agents Chemother. 2017, 61, e02429-16. [Google Scholar] [CrossRef]
  231. Saavedra-Lira, E.; Pérez-Montfort, R. Energy Production in Entamoeba Histolytica: New Perspectives in Rational Drug Design. Arch. Med. Res. 1996, 27, 257–264. [Google Scholar]
  232. de Carvalho Gallo, J.C.; de Mattos Oliveira, L.; Araújo, J.S.C.; Santana, I.B.; dos Santos Junior, M.C. Virtual Screening to Identify Leishmania Braziliensis N-Myristoyltransferase Inhibitors: Pharmacophore Models, Docking, and Molecular Dynamics. J. Mol. Model. 2018, 24, 260. [Google Scholar] [CrossRef]
  233. Gundampati, R.K.; Sahu, S.; Shukla, A.; Pandey, R.K.; Patel, M.; Banik, R.M.; Jagannadham, M.V. Tryparedoxin Peroxidase of Leishmania Braziliensis: Homology Modeling and Inhibitory Effects of Flavonoids for Anti-Leishmanial Activity. Bioinformation 2014, 10, 353–357. [Google Scholar] [CrossRef]
  234. Venkatesan, S.K.; Saudagar, P.; Shukla, A.K.; Dubey, V.K. Screening Natural Products Database for Identification of Potential Antileishmanial Chemotherapeutic Agents. Interdiscip. Sci. 2011, 3, 217–231. [Google Scholar] [CrossRef]
  235. Maamri, S.; Benarous, K.; Yousfi, M. Identification of 3-Methoxycarpachromene and Masticadienonic Acid as New Target Inhibitors against Trypanothione Reductase from Leishmania Infantum Using Molecular Docking and ADMET Prediction. Molecules 2021, 26, 3335. [Google Scholar] [CrossRef]
  236. Inacio, J.D.F.; Fonseca, M.S.; Limaverde-Sousa, G.; Tomas, A.M.; Castro, H.; Almeida-Amaral, E.E. Epigallocathechin-O-3-Gallate Inhibits Trypanothione Reductase of Leishmania Infantum, Causing Alterations in Redox Balance and Leading to Parasite Death. Front. Cell. Infect. Microbiol. 2021, 11, 640561. [Google Scholar] [CrossRef]
  237. Amiri-Dashatan, N.; Rezaei-Tavirani, M.; Ranjbar, M.M.; Koushki, M.; Mousavi Nasab, S.D.; Ahmadi, N. Discovery of Novel Pyruvate Kinase Inhibitors Against Leishmania Major Among FDA Approved Drugs Through System Biology and Molecular Docking Approach. Turk. J. Pharm. Sci. 2021, 18, 710–717. [Google Scholar] [CrossRef] [PubMed]
  238. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Žídek, A.; Potapenko, A.; et al. Highly Accurate Protein Structure Prediction with AlphaFold. Nature 2021, 596, 583–589. [Google Scholar] [CrossRef] [PubMed]
  239. Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yordanova, G.; Yuan, D.; Stroe, O.; Wood, G.; Laydon, A.; et al. AlphaFold Protein Structure Database: Massively Expanding the Structural Coverage of Protein-Sequence Space with High-Accuracy Models. Nucleic Acids Res. 2022, 50, D439–D444. [Google Scholar] [CrossRef] [PubMed]
Figure 1. The biochemical characterization of FDA-approved drugs in Leishmania infection including the mode of action against the parasites.
Figure 1. The biochemical characterization of FDA-approved drugs in Leishmania infection including the mode of action against the parasites.
Pathogens 12 00706 g001
Figure 2. The application of various computational tools and strategies including OMICS, SBDD, and immunoinformatics for the rational design of novel therapeutics against Leishmania.
Figure 2. The application of various computational tools and strategies including OMICS, SBDD, and immunoinformatics for the rational design of novel therapeutics against Leishmania.
Pathogens 12 00706 g002
Figure 3. Depiction of the leishmanicidal potential of novel therapeutics targeted to the parasite’s specific survival pathways.
Figure 3. Depiction of the leishmanicidal potential of novel therapeutics targeted to the parasite’s specific survival pathways.
Pathogens 12 00706 g003
Figure 4. Docked complexes showing the interactions between the inhibitors and target proteins of Leishmania: Ld-CC ion channel is shown in green in the cartoon model and the inhibitor ZINC29590262 is in red in the stick model (A). The LdUGM, LdPPDK, and Ld-APX enzymes are shown in blue, pink, and brown in the cartoon model, respectively, while the corresponding inhibitors 6064500 (yellow), Z220582104 (black), and ML-240 (rainbow) are shown in the stick model inside the pocket of the respective proteins (BD).
Figure 4. Docked complexes showing the interactions between the inhibitors and target proteins of Leishmania: Ld-CC ion channel is shown in green in the cartoon model and the inhibitor ZINC29590262 is in red in the stick model (A). The LdUGM, LdPPDK, and Ld-APX enzymes are shown in blue, pink, and brown in the cartoon model, respectively, while the corresponding inhibitors 6064500 (yellow), Z220582104 (black), and ML-240 (rainbow) are shown in the stick model inside the pocket of the respective proteins (BD).
Pathogens 12 00706 g004
Table 2. Identification of novel antileishmanial drugs specific to biochemical pathways critical for the survival of Leishmania donovani.
Table 2. Identification of novel antileishmanial drugs specific to biochemical pathways critical for the survival of Leishmania donovani.
PathwayDrug TargetDrug CandidateMode of
Sterol Biosynthesis PathwaySqualene epoxidaseSpiro[indole-3,3′-pyrrolizidine]-2-oneDNA topoisomerase IB inhibitor.[67,68]
HMGR enzymeMevastatinHampers HMGR activity.[69,70]
Sterol alpha-14 demethylaseAvodartInduces ROS and causes apoptosis in the parasite.[71]
HMGR enzymeGlycyrrhizic acidInhibits HMGR enzyme.[72]
Purine Salvage PathwaymRNA translation5-fluorouracil
Binds to RNA and blocks cell growth.[73,74]
Glycolytic PathwayGAPDHArtesunateInhibits the parasites’ glycolytic enzymes GPDH.[75,76]
Folate Biosynthesis PathwayDHFRMethotrexate (MTX, 1)Inhibits DHFR.[77]
Trimethoprim (TMP, 2)[77,78]
ZINC57774418 (Z18)Inhibits DHFR activity.[79]
ZINC69844431 (Z31)[79]
ZINC71746025 (Z25)[79]
D11596 (DB96)[79]
5-(3,5-dimethoxybenzyl) pyrimidine-2,4-diamine[80]
DHFR and PTR12-(4-((2,4-dichlorobenzyl)oxy)phenyl)-1H-benzo[d]imidazoleDHFR-TS/PTR1 inhibitors.[81]
Trypanothione PathwayTRTrichloro [1,2-ethanediolato-O,O’]-tellurate (AS101)Induces ROS-mediated apoptosis by binding to TR cysteine residues.[82]
β-sitosterol CCLInhibit TR activity.[83]
Hypusine PathwaySpermidine synthaseHypericinROS and spermidine reduction.[84,85]
Table 3. The major computational tools used in the in silico analysis for the identification of novel leishmanicidal compounds derived from the available databases.
Table 3. The major computational tools used in the in silico analysis for the identification of novel leishmanicidal compounds derived from the available databases.
S. NoResourcesDescriptionsWeblinkRef.
1.TriTrypDBFor Leishmania and Trypanosoma, an integrated genomic and functional genomic resource is available. (accessed on 8 December 2022)[166]
2.LeishCycL. major biochemical pathway database.¼LEISH (accessed on 7 December 2022)[167]
3.L. amazonensis
genome DB
The genome of L. amazonensis has been sequenced and annotated. (accessed on 6 December 2022)[168]
Protozoa section)
Annotations and sequences of 5 Leishmania species were curated.http://www.genedb.or (accessed on 8 December 2022)[169]
5.EuPathDBFor eukaryotic pathogens, there is a pathogen genomics resource. (accessed on 9 December 2022)[170]
6.LmSmdBRegulatory pathways and biological networks of L. major. (accessed on 9 December 2022)[171]
7.LeishMicrosatDBRepeat sequences from six Leishmania species are included in a database. (accessed on 11 December 2022)[172]
8.TrypsNetDBProtein interactions and annotations for trypanosomatid parasites that have been experimentally verified as well as predicted. (accessed on 5 December 2022)[173]
9.LeishDBNoncoding RNAs and coding gene reannotation in L. braziliensis. (accessed on 7 December 2022)[174]
10.List of putative
Lead compounds and drug targets with predicted antileishmanial activity. on 6 December 2022)[175]
11.L. major metabolic networkGenome-scale metabolic network of Leishmania major (iAC560). (accessed on 10 December 2022)[176]
Table 4. List of novel drugs explored by chemoinformatics against Leishmania donovani.
Table 4. List of novel drugs explored by chemoinformatics against Leishmania donovani.
DrugStructurePathwayTarget ProteinMode of ActionRef.
Z220582104Pathogens 12 00706 i006Glucose synthesis and alanine influxPyruvate phosphate dikinase (PPDK)Inhibits the pyruvate phosphate dikinase enzyme that helps in
  • Alanine entry
  • Mannogen synthesis from lactate
  • ATP formation
CID 6064500Pathogens 12 00706 i007Β-Galf synthesis
Role in pathogenesis
UDP-galactopyranose mutase (UGM)Inhibits the UDP-galactopyranose mutase (UGM) enzyme
  • It catalyzes the UDP galacto pyranose (UDP-Galp) to UDP-galacto furanose (UDP-Galf)
  • UGM helps in plays an important role in the pathogenesis of the parasite
ZINC96021026Pathogens 12 00706 i008TryparedoxinAscorbate peroxidase (APX)Inhibits the ascorbate peroxidase enzyme activity
  • It is a redox enzyme (tryparedoxin pathway)
  • It helps in H2O2 removal or its detoxification
ZINC29590262Pathogens 12 00706 i009Ca2+ related pathwaysCalcium channelInhibits calcium channel that hampers flagellar motion
  • Inhibit mitochondrial function and oxidative metabolism
  • Affects the Ca2+ pathways
Table 5. List of proteins and drugs explored by the structure-based drug design against different Leishmania species. The cartoon model of the protein structure was generated using the PyMol tool and shown in different colors. The 2D structures of the compounds were generated by ChemSketch 3D.
Table 5. List of proteins and drugs explored by the structure-based drug design against different Leishmania species. The cartoon model of the protein structure was generated using the PyMol tool and shown in different colors. The 2D structures of the compounds were generated by ChemSketch 3D.
S. NoLeishmania
Target ProteinsStructure of the ProteinCompoundRef.
1.Leishmania majorN-myristoyl transferase (PDBID: 5A27)Pathogens 12 00706 i010ZINC35426134
Pathogens 12 00706 i011
2.Leishmania majorTryparedoxin peroxidase
Pathogens 12 00706 i012Taxifolin
Pathogens 12 00706 i013
Pathogens 12 00706 i014
3.Leishmania infantumTrypanothione reductase (PDB ID: 2JK6)Pathogens 12 00706 i015Beta-Amyrin Acetate
Pathogens 12 00706 i016
Pathogens 12 00706 i017
Pathogens 12 00706 i018
Pathogens 12 00706 i019
4.Leishmania infantumTrypanothione reductase (PDB ID: 5EBK)Pathogens 12 00706 i020Masticadienonic acid
Pathogens 12 00706 i021
5.Leishmania infantumTrypanothione reductase (PDB ID: 2JK6)Pathogens 12 00706 i022Epigallocatechin Gallate
Pathogens 12 00706 i023
6.Leishmania mexicanaPyruvate kinase (PDB ID: 3PP7)Pathogens 12 00706 i024Irinotecan[237]
Pathogens 12 00706 i025
Pathogens 12 00706 i026
Pathogens 12 00706 i027
Pathogens 12 00706 i028
Pathogens 12 00706 i029
Pathogens 12 00706 i030
Pathogens 12 00706 i031
Pathogens 12 00706 i032
Pathogens 12 00706 i033
Pathogens 12 00706 i034
7.Leishmania mexicanaGlucose-6-phosphate isomerase (PDB ID: 1T10)Pathogens 12 00706 i035Artesunate[75]
Pathogens 12 00706 i036
Pathogens 12 00706 i037
Leishmania mexicanaTriosephosphate isomerase (PDB ID: 2Y63)Pathogens 12 00706 i038Mefloquine
Leishmania mexicanaGlycerol-3-phosphate dehydrogenase (PDB ID: 1M67)Pathogens 12 00706 i039
Leishmania mexicanaGlyceraldehyde-3-phosphate dehydrogenase (PDB ID: 1I33)Pathogens 12 00706 i040Pathogens 12 00706 i041
Leishmania mexicanaPyruvate kinase (PDB ID: 3PP7)Pathogens 12 00706 i042
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Singh, R.; Kashif, M.; Srivastava, P.; Manna, P.P. Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host. Pathogens 2023, 12, 706.

AMA Style

Singh R, Kashif M, Srivastava P, Manna PP. Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host. Pathogens. 2023; 12(5):706.

Chicago/Turabian Style

Singh, Ranjeet, Mohammad Kashif, Prateek Srivastava, and Partha Pratim Manna. 2023. "Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host" Pathogens 12, no. 5: 706.

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop